

**Ganesh S. Palapattu, MD, FACS**  
**The George F. and Sandy G. Valassis Professor and Chair of Urology**  
University of Michigan  
Department of Urology  
3875TC, 1500 East Medical Center Drive SPC5330  
Ann Arbor, Michigan 48109-5330  
Phone: 734-763-9269  
Fax: 734-936-9127  
Email: gpalapat@med.umich.edu

## **Education and Training**

### **Education**

01/1988-01/1992 BA, University of Texas Humanities/South Asian Studies, Austin, Texas  
08/1992-05/1997 MD, Baylor College of Medicine, Houston, Texas

### **PostDoctoral Training**

07/1997-06/1998 Internship, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California  
07/1998-06/2002 Residency, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California  
07/2002-06/2003 Chief Resident, David Geffen School of Medicine at UCLA, Los Angeles, California  
08/2003-07/2005 Postdoctoral Fellow, Urologic Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland

### **Additional Education**

05/2013 Certificate, Lean Enterprise Institute Manager's Workshop, Cambridge, Massachusetts  
03/2015-05/2015 University of Michigan Linkage Leadership Academy, Ann Arbor, Michigan  
10/2017-11/2017 Harvard T.H. Chan School of Public Health - Leadership Development for Physicians in Academic Health Centers, Boston, Massachusetts

## **Certification And Licensure**

### **Certification**

02/2008-02/2028 American Board of Urology #14206  
09/2020-08/2022 Basic Life Support

### **Licensure**

03/1998-03/2023 United States, DEA Registration  
08/2009-11/2022 State of Texas, Medical License  
07/2012-07/2025 State of Michigan, Controlled Substance  
07/2012-07/2025 State of Michigan, Medical License  
07/2016-07/2023 State of Michigan, Controlled Substance  
06/2017-03/2023 United States, DEA Registration

## **Academic, Administrative, Clinical, Research and Military Appointments**

### **Academic Appointments**

08/2003-07/2005 Clinical Instructor, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland  
09/2005-07/2009 Assistant Professor, Instructional Track, Department of Urology, University of Rochester School of Medicine, Rochester, New York  
09/2006-07/2009 Assistant Residency Program Director, Department of Urology, University of Rochester School of Medicine, Rochester, New York

09/2007-07/2009	Assistant Professor, Department of Oncology, University of Rochester School of Medicine, Rochester, New York
10/2007-07/2009	Assistant Professor, Department of Pathology & Laboratory Medicine, University of Rochester School of Medicine, Rochester, New York
10/2009-07/2012	Associate Member, The Methodist Hospital Research Institute, Houston, Texas
01/2011-07/2012	Associate Professor of Clinical Urology, The Methodist Hospital / Weill Cornell Medical College, Houston, Texas
09/2012-05/2016	Associate Professor, Instructional Track, Department of Urology, University of Michigan - Michigan Medicine, Ann Arbor, Michigan (Tenured)
11/2015-present	Adjunct Professor of Urology, Medical University of Vienna, Vienna, Austria
09/2016-present	Professor, Instructional Track, Department of Urology, University of Michigan - Michigan Medicine, Ann Arbor, Michigan (Tenured)

### **Administrative Appointments**

10/2015-present	Co-Director, Genitourinary (GU) Oncology Program, University of Michigan - Michigan Medicine Comprehensive Cancer Center, Ann Arbor, Michigan
10/2017-present	Urology Care Foundation Physician Scientist Residency Training Program Director, University of Michigan - Michigan Medicine, Ann Arbor, MI
02/2019-present	Chair in Urology Surgery, University of Michigan - Ann Arbor, Ann Arbor, Michigan
02/2019-present	Chair, Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
09/2021-present	Chair Sponsor and Special Advisor to the Senior Associate Dean for Clinic Affairs and UMMG Executive Director, University of Michigan Medical Group, Ann Arbor, Michigan

### **Clinical Appointments**

08/2009-07/2012	Chief of Urologic Oncology, The Methodist Hospital, Houston, Texas
09/2012-02/2019	Chief of Urologic Oncology, University of Michigan - Michigan Medicine, Ann Arbor, Michigan
09/2012-present	The George F. and Sandy G. Valassis Professor of Urology, University of Michigan - Michigan Medicine, Ann Arbor, Michigan

### **Clinical Interests**

- **Prostate Cancer** - high-risk prostate cancer, robotic prostatectomy, nerve-sparing surgical techniques
- Kidney Cancer** - open and minimally invasive surgical approaches (i.e., laparoscopic and robotic) for small and large renal masses with vascular involvement
- Testis Cancer** - open retroperitoneal lymph node dissection for large post-chemotherapy residual masses

### **Research Interests**

- The long-term objective of our lab is to improve the outcomes of men with prostate cancer. Specifically, we are interested in i) employing metabolomics to understand the biology of prostate cancer progression, ii) dissecting the role of tumor stromal-epithelial interactions in prostate cancer metastasis, iii) molecular profiling of urologic cancers, iv) examining the role of platelets in the tumor microenvironment, and v) testing NK cell therapy in prostate and bladder cancer. We have also had collaborations interrogating the utility of novel in vivo imaging devices to be used during prostate cancer surgery and the efficacy of innovative nanotechnology devices for sustained drug delivery.

### **Grants**

#### **Current Grants**

*Defining the Biological Arc of Grade Group 2 Prostate Cancer* NIH-DHHS-US- 21-PAF01820  
Co-I with Effort (Principal Investigator: Salami, Simpa)  
09/2021-08/2026. \$1,950,000

*Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer* NIH-DHHS-US- 20-PRE00121  
Co-I with Effort (Principal Investigator: Daniel Spratt)  
12/2020-11/2025. \$1

*Seeing the Unseen: Using Machine Learning and Molecular Profiling to Characterize Prostate Cancer Visibility on Multiparametric MRI* Prostate Cancer Foundation- 20-PAF08390  
Co-I with Effort (Principal Investigator: Simpa Salami; Arul Chinnaiyan; Arvind Rao)  
09/2020-08/2022. \$1,000,000

*Defining Molecular Features of Tumor Lethality and Treatment Response in Metastatic Prostate Cancer* Prostate Cancer Foundation- 19-PAF05674 - Mentor to PI  
Jeffrey Tosoian, PI  
11/2019-10/2022. \$225,000

*5 P50 CA 186786 07: Michigan Prostate SPORE* NIH-DHHS-US  
Arul Chinnaiyan; Elisabeth Heath; Ganesh Palapattu, PI  
09/2019-08/2024. \$9,215,218 (\$1,783,426)

*5 P50 CA186786 07: Michigan Prostate SPORE Project 2: Integrating a Novel MIPS-Based Next-Generation Sequencing Urine Assay for the Early Detection of Unfavorable Risk Prostate Cancer* NIH-DHHS-US  
Ganesh Palapattu, PI  
09/2019-08/2024. \$1,981,090 (\$396,218)

*5 P50 CA186786 07: Michigan Prostate SPORE Admin Core* NIH-DHHS-US  
Arul Chinnaiyan; Elisabeth Heath; Ganesh Palapattu, PI  
09/2019-08/2024. \$145,125 (\$29,025)

*University of Michigan Physician Scientist Residency Training Program - Funds Used for Trainees Urology Care* Foundation- 18-PAF00400  
Ganesh Palapattu, PI  
07/2019-06/2027. \$225,000 (\$75,000)

*R01CA227559: Metabolic Rewiring Promotes AA PCa by Regulating Stromal-Epithelial Interaction* Baylor/NIH  
Arun Sreekumar, Ganesh Palapattu, PI  
07/2019-06/2024. \$1,926,284 (\$408,656)

*2 P50 CA186786-07S1: Michigan Prostate SPORE* NIH-DHHS-US- 14-PAF00108; 14-PAF00108; 19-PAF00149; 20-PAF02244  
Arul M Chinnaiyan, PI  
09/2014-08/2024. \$11,149,056

*5 T32 CA180984-09: Advanced Training in Urologic Oncology* NIH-DHHS-US  
Ganesh Palapattu, Brent Hollenbeck, PI  
08/2014-06/2024. \$1,805,204 (\$285,032)

### **Submitted Grants**

*University of Michigan Senescence Tissue Mapping Center* NIH-DHHS-US- 21-PAF06320  
Co-I with Effort (Principal Investigator: Gudjonsson, Johann E;Bitzer, Markus;Hodgin, Jeffrey B)  
12/2021-11/2026. \$16,819,018

### **Past Grants**

*Molecular Characterization of Radiation Resistance in Prostate Cancer* Austrian Society for Urology (- 21-PAF06027  
Ganesh Palapattu, PI  
01/2021-12/2021. \$6,056 (\$6,056)

*Metabolic rewiring promotes AA PCa by regulating stromal-epithelial interaction R01* SubK-NIH-DHHS-US through a consortium with Baylor College of Medicine- 18-PAF08167  
Ganesh Palapattu, PI  
07/2019-06/2020. \$100,863

*The Cell Surface Amino Acid Glypican-1 (GPC-1) as a Potential Target for NK92 Cell-Based Therapy* Minomic International Ltd- 17-PAF08407  
Co-I without Effort (Principal Investigator: Alexander Zaslavsky)  
03/2018-02/2019. \$84,986

*P07-R-2017: Comprehensive Molecular Profiling of Renal Cell Carcinoma* University of Michigan Health System /Peking University Health Science Center  
Ganesh Palapattu, PI  
10/2017-06/2022. \$300,000 (\$148,479)

*Molecular Profiling of Serially Targeted Biopsy Tissue to Predict Treatment Failure in Men Undergoing Focal Laser Photothermally Ablation for Prostate Cancer* American Society for Laser Med- 17-PAF06110  
Co-I without Effort (Principal Investigator: Arvin George)  
07/2017-06/2018. \$70,000 (\$35,000)

*The cell surface amino acid glypican-1 (GPC-1) as a potential target for NK92 cell -based therapy.* Minomic International Ltd- 17-PAF00520  
Co-I without Effort (Principal Investigator: Alexander Zaslavsky)  
09/2016-08/2017. \$39,680 (\$39,680)

*Molecular Profiling of Serial Targeted Biopsy Tissue to Predict Progression of Low to High Grade Prostate Cancer in Men on Active Surveillance.* Urology Care Foundation- 16-PAF01036 - Mentor to PI  
Co-I (Principal Investigator: Simpa Salami)  
07/2016-06/2017. \$40,000

*Molecular Characterization of the Biologically Dominant Nodule in Multifocal Prostate Cancer with N1 disease* Prostate Cancer Foundation- 16-PAF04867 - Mentor to PI  
Co-I (Principal Investigator: Simpa Salami)  
06/2016-06/2019. \$225,000

*PCF-701640: Testing Targeted NK (TaNK) Cell Therapy in Prostate Cancer* Prostate Cancer Foundation- 15-PAF06677  
Ganesh Palapattu, PI  
09/2015-09/2019. \$600,000 (\$300,000)

*P50-CA186786: SPORE (Specialized Program of Research Excellence) in Prostate Cancer- Administrative Core.* NCI/NIH- 14-PAF00108  
Ganesh Palapattu, Arul Chinnaiyan, PI  
09/2014-08/2019. \$808,085 (\$161,611)

*P50-CA186786: SPORE Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer.* NCI/NIH- 14-PAF00108  
Ganesh Palapattu, Arul Chinnaiyan, PI  
09/2014-08/2019. \$11,189,000 (\$1,631,589)

*5 T32 CA180984-04: Advanced Training in Urologic Oncology.* NIH-DHHS-US- 14-PAF00984  
Ganesh Palapattu, Brent Hollenbeck, PI  
08/2014-06/2019. \$797,769 (\$147,504)

*086402: San Antonio Center for Biomarkers of Risk for Prostate Cancer (SABOR)* SubK-NIH-DHHS-US through a consortium with The University of Texas Health- 17-PAF04170  
Co-I without Effort (Principal Investigator: John Thomas Wei)  
07/2014-03/2020. (\$15,000)

*NCT-02209584: An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris?) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists.* Myriad Genetics- 14-PAF03506  
Co-I without Effort (Principal Investigator: Todd Morgan)  
01/2014-12/2015. \$51,993

*Biomarkers and clinical parameters associated with Gleason score upgrading.* SubK-NIH-DHHS-US through a consortium with University of Texas Health Sci- 14-PAF04860  
Co-I without Effort (Principal Investigator: John Thomas Wei)  
07/2013-06/2014. \$50,000 (\$182,760)

*3 P30 CA046592-28S5: University of Michigan Cancer Center Support Grant Year 6* NIH-DHHS-US- 11-PAF04124; 18-PAF00871; 17-PAF00945  
Co-I with Effort (Principal Investigator: Eric R Fearon)  
09/2012-05/2018. \$37,331,617

*3 P30 CA046592-28S3: P30 Cancer Center Admin Supp 2017 Early Drug Development Opportunities Program (EDDOP) Leadership* NIH-DHHS-US- 11-PAF04124; 17-PAF00945; 18-PAF00871  
Co-I with Effort (Principal Investigator: Eric R Fearon)  
09/2012-05/2018. \$37,331,617

*3 P30 CA046592-28S3: University of Michigan Cancer Center Support Grant Year 6* NIH-DHHS-US- 11-PAF04124; 17-PAF00945  
Co-I with Effort (Principal Investigator: Eric Fearon)  
09/2012-05/2018. \$29,985,989

*4 P30 CA046592-28: Michigan Medicine Cancer Center Support Grant* NIH-DHHS-US- 11-PAF04124  
Co-I with Effort (Principal Investigator: Eric Fearon)  
09/2012-05/2017. \$28,419,251 (\$6,237,326)

*Metabolomic Profiling to Distinguish Racially Distinct Prognostic Markers in Prostate Cancer.* Department of Defense, Health Disparity Research Award- W81XWH-12-1-0130  
Ganesh Palapattu, Arun Sreekumar, PI  
09/2012-09/2015. \$139,558 (\$114,033)

*A Label-Free and Chemical-Selective Microendoscope to Enhance Prostate Cancer Surgical Outcomes.* Department of Defense, Prostate Cancer Research Program- W81XWH-12-1-0375  
Co-I (Principal Investigator: Stephen Wong)  
09/2012-09/2015. \$60,555 (\$20,185)

*U01-CA-167234: Metabolomic Profiling and the Biological Basis of Racial Disparity in Prostate Cancer.* NCI/NIH- UCA167234A  
Ganesh Palapattu, Arun Sreekumar, PI  
09/2012-09/2015. \$123,749 (\$40,928)

*Consortium Agreement # 27010021-0016: A Label-Free and Chemical-Selective Microendoscope To Enhance Prostate Cancer Surgical Outcomes.* SubK-Army-DoD-US through a consortium with Methodist Hospital - Houston- 12-PAF07176  
Ganesh Palapattu, PI  
09/2012-09/2015. \$60,555 (\$20,185)

*5600887963: Metabolomic Profiling to Distinguish Racially Distinct Prognostic Markers in Prostate Cancer.* SubK-Army-DoD-US through a consortium with Baylor College of Medicine- 12-PAF07089  
Ganesh Palapattu, PI  
09/2012-08/2015. \$227,940 (\$53,535)

*W81XWH-12-1-0507: SPANXB2 and Prostate Cancer Progression (PC110674).* Army-DoD-US- 12-PAF06974 - Mentor to PI  
Co-I (Principal Investigator: Hangwen Li)  
09/2012-09/2014. \$112,067 (\$53,904)

*U01-CA167234: Metabolomic Profiling and the Biological Basis of Radical Disparity in Prostate Cancer.* SubK-NIH-DHHS-US through a consortium with Baylor College of Medicine- 12-PAF06952

Ganesh Palapattu, PI

08/2012-08/2017. \$123,749 (\$18,340)

*P30 CA046524: Michigan Medicine Comprehensive Cancer Center Support Grant* University of Michigan

Co-I (Principal Investigator: Eric Fearon)

06/2012-05/2018. \$3,923,710

*Novel Therapy for Patients with Advanced Prostate Cancer Using Co-Dependent Tumor-Specific T Cells Expressing IL7 and IL7R.* Department of Defense, New Investigator Award- W81XWH-11-1-0625

Ganesh Palapattu, A. Vera, PI

09/2011-09/2014. \$136,310

*Nanochannel Technology for the Constant and Sustained Delivery of Testosterone from Implantable Devices.*

Industry sponsor: NanoMedical Systems, Inc.

Ganesh Palapattu, Alessandro Grattoni, PI

08/2011-08/2012. \$600,000

*1U54CA149196-01: Tumor Initiating Properties of Circulating Tumor Cells in Men with Advanced Prostate Cancer.*

U54 NCI Center for Systematic Modeling of Cancer Development

Ganesh Palapattu, Stephen Wong, PI

01/2011-06/2012. \$75,000

*SPORE (Specialized Program of Research Excellence) in Prostate Cancer.* NIH/NCI- SPORE P50 CA69568

Ganesh Palapattu, Arul Chinnaiyan, PI

06/2008-05/2014. \$1,500,000

*The Isolation and Characterization of Human Prostate Cancer Stem Cells.* Department of Defense, Physician research training award- W81XWH-08-1-0508

Ganesh Palapattu, PI

03/2008-02/2012. \$133,166

*Label-Free Antibody Arrays for Cancer Diagnostics.* NIH – NCI/SBIR Phase I- HHSN261200700041C

Co-I (Principal Investigator: Christopher Striemer)

09/2007-03/2008. \$127,110

*Bone Marrow Derived Cells (BMDCs), Inflammation and Prostate Carcinogenesis.* Edwin Beer Award - NY Academy of Sciences

Ganesh Palapattu, PI

07/2007-06/2008. \$80,000

*Bone Marrow Derived Cells (BMDCs) and Prostate Carcinogenesis.* American Urological Association/NE section; Young Investigator Award

Ganesh Palapattu, PI

01/2007-12/2008. \$30,000

*Identification of Tumor Initiating Human Prostate Cancer Stem Cells.* Edelman Gardner Foundation

Ganesh Palapattu, PI

07/2006-06/2007. \$50,000

*Bone Marrow Derived Cells (BMDCs) and Prostate Carcinogenesis.* Prostate Cancer Foundation; Competitive Research Award

Ganesh Palapattu, PI

02/2006-02/2008. \$100,000

## **Honors and Awards**

### **International**

2006

Prostate Cancer Foundation Competitive Research Award

## **National**

1995-1996	Howard Hughes Research Training Fellowship for Medical Students
2003-2005	American Foundation for Urologic Disease (AFUD) Post-Graduate Fellowship - Johns Hopkins University
2006	Northeastern Section of the American Urological Association Young Investigator Award
2007-2008	Edwin Beer Award - The New York Academy of Sciences
2008-2013	Astellas/American Urological Association Foundation Rising Star in Urology Award
2008-2013	Physician Research Training Award - Department of Defense
2010	American Urological Association International Exchange Scholar (India)

## **Regional**

1988	Texas State Champion French Horn Soloist - University Interscholastic League
1991-1992	Endowed Presidential Scholarship in the Humanities
1991	Phi Beta Kappa
1992	Summa Cum Laude - University of Texas at Austin
2001	First Place - Los Angeles Urological Society Essay Contest

## **Institutional**

1988-1989	Music Scholarship, French Horn Performance - University of Texas at Austin
2003	Willard E. Goodwin Resident Teaching Award - University of California, Los Angeles
2006	Edelman Gardner Research Award - Wilmot Cancer Center
2009	Medical Student Mentoring Award - University of Rochester Medical School Surgery Interest Group
2009	Robert S. Davis Faculty Teaching Award - University of Rochester Department of Urology

## **Memberships in Professional Societies**

2003-present	Member, American Urological Association
2005-2009	Member, Northeastern Section of the American Urological Society
2005-present	Member, American Association of Cancer Research
2005-present	Member, Indian American Urological Association
2005-present	Member, Johns Hopkins Medical and Surgical Association
2005-present	Member, Southwest Oncology Group
2009-2012	Associate Member, Center for Cell and Gene Therapy - Baylor College of Medicine
2009-2012	Associate Member, The Methodist Hospital Research Institute
2009-2012	Member, Southeastern Section of the American Urological Association
2009-present	Fellow, American College of Surgeons
2009-present	Member, Society of Urologic Oncology
2010-present	Member, American Society of Clinical Oncology
2012-present	Member, North Central Section of the American Urological Association
2014-present	Member, Urological Research Society
2015-present	Member, Research Grants and Investigator Support Committee - American Urological Association
2016-present	Member, European Association of Urology
2019-present	Member, Society for Basic Urologic Research, Inc.
2019-present	Member, Société Internationale d'Urologie
2020-present	Member, American Society for Clinical Investigations
2020-present	Member, Royal College of Physicians and Surgeons of Glasgow
2021-present	Member, American Association of Genitourinary Surgeons

## Editorial Positions, Boards, and Peer-Review Service

### Study Sections

#### International

2020 External Application Reviewer for PASSPORT's (Personalized Assessment of Prostate Cancer) application to be designated as a Center of Clinical Excellence in the Region of Southern Denmark (Ad Hoc)

#### National

2006 Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2007 Scientific Peer Reviewer - Broad Medical Foundation

2007 Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2009 Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2010 Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2010 Study Section Chair, Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2013 Study Section Chair, Scientific Peer Reviewer - Prostate Cancer Research Program, United States Department of Defense

2014-2015 Reviewer - Research Scholars Program Review, American Urological Association

2018 Scientific Peer Reviewer - ZCA1 RPRB-N (M1) - NCI/NIH - Prostate SPORE Program

2019-present Dana Farber/Harvard Cancer Center SPORE in Prostate Cancer External Advisory Board

2019-present External Advisory Board to University of Alabama, Cancer Center Program with an Emphasis on the Genitourinary Program and Radiation Oncology (Ad Hoc)

2019-present Howard University Division of Urology External Advisory Board (Ad Hoc)

2019-present Memorial Sloan Kettering Cancer Center T32 Advisory Committee (Ad Hoc)

2020 2020 AUA Research Forum: Early Career Investigators Showcase Reviewer

2020 National Cancer Institute (NCI) Review - Clinical & Translational R21 and Omnibus R03 (Ad Hoc)

2021 National Cancer Institute (NCI) Review - P20 Partnerships CC & Institutions Serving Underserved Health Disparity Populations and Underrepresented Students (ISUPS) (Ad Hoc)

#### Institutional

2019-present University of Michigan P01 Internal Advisory Board for "The Biology of Prostate Cancer Skeletal Metastases" (Ad Hoc)

#### Editorial Boards

2015-present Basic/Translational Science Survey Review Board, Urologic Oncology: Seminars and Original Investigations

2017-present Current Opinion in Urology

2017-present European Urology Oncology

#### Journal Reviewer

2004-2009 Cancer

2005-present European Urology

2005-present Urology

2006-present Journal of Urology

2006 Asian Journal Of Andrology



2007	Cancer Epidemiology, Biomarkers and Prevention
2007	Stem Cells
2008-2015	Prostate Cancer and Prostate Disease
2008-present	Clinical Cancer Research
2009-2010	Cancer Research
2009-present	Expert Reviews in Anti-Cancer Therapy
2010	Vaccine
2012	Indian Journal of Urology
2013-present	Prostate Cancer and Prostate Disease
2013	Cancer Research
2015-present	Urologic Oncology: Seminars and Original Investigations

## Teaching

### Advanced Post Graduate Fellow

07/2014-03/2016	Takahiro Osawa, MD, University of Michigan - Michigan Medicine
07/2015-06/2017	Greg Auffenberg, MD, University of Michigan - Michigan Medicine
04/2016-07/2016	Peter Oestergren, MD, University of Copenhagen, Denmark
07/2016-06/2017	Simpa Salami, MD, University of Michigan - Michigan Medicine
07/2016-06/2018	Deborah Kaye, MD, University of Michigan - Michigan Medicine
07/2017-06/2019	Parth Modi, MD, University of Michigan - Michigan Medicine
07/2018-06/2020	Jeff Tosoian, MD, MPH, University of Michigan - Michigan Medicine
07/2019-present	Randy Vince, MD, University of Michigan - Michigan Medicine
07/2020-present	Kristian Stensland, MD, MPH, University of Michigan - Michigan Medicine

### Clinical Fellow

10/2012-06/2013	Bruce Jacobs, MD, University of Michigan - Michigan Medicine
07/2013-06/2014	Florian Schroeck, MD, University of Michigan - Michigan Medicine
07/2014-06/2015	Paul Womble, MD, University of Michigan - Michigan Medicine
07/2015-06/2016	Simpa Salami, MD, University of Michigan - Michigan Medicine
07/2016-06/2017	Lindsey Herrel, MD, University of Michigan - Michigan Medicine
07/2017-06/2018	Tudor Borza, MD, University of Michigan - Michigan Medicine
07/2018-06/2019	Deborah Kaye, MD, University of Michigan - Michigan Medicine
07/2019-06/2020	Parth Modi, MD, University of Michigan - Michigan Medicine
07/2020-present	Jeffrey Tosoian, MD, MPH, University of Michigan - Michigan Medicine

### Faculty Member

09/2012-present	Todd Morgan, MD, University of Michigan - Michigan Medicine
09/2012-present	Alexander Zaslavsky, PhD, University of Michigan - Michigan Medicine
08/2016-present	Arvin George, MD, University of Michigan - Michigan Medicine
09/2016-present	Samuel Kaffenberger, MD, University of Michigan - Michigan Medicine
07/2017-present	Simpa Salami, MD, University of Michigan - Michigan Medicine
07/2017-present	Lindsey Herrel, MD, University of Michigan - Michigan Medicine

### Medical Student

01/2005-07/2009	Sarel Gaur, University of Rochester
01/2005-07/2009	David Stoddard, University of Rochester
01/2005-07/2009	David Mener, University of Rochester
01/2005-07/2009	Karin Westesson, University of Rochester

01/2005-07/2009	Brock O'Neil, University of Rochester
01/2005-07/2009	Deepak Sobti, University of Rochester
01/2005-07/2009	Thomas Pashilades, University of Rochester
01/2006-07/2008	Matthew Swenson, University of Rochester
10/2009-07/2012	Harsha Mittakanti, Baylor College of Medicine
10/2009-07/2012	Abhinav Khanna, Baylor College of Medicine
11/2012-05/2014	Brian Orr, University of Michigan - Michigan Medicine
01/2013-05/2014	Zachary Koloff, University of Michigan - Michigan Medicine
02/2014-05/2015	Brady Miller, University of Michigan - Michigan Medicine
07/2014-05/2015	Udit Singhal, University of Michigan - Michigan Medicine

### **Postdoctoral Fellow**

08/2012-05/2015	Hangwen Li, PhD, University of Michigan - Michigan Medicine
05/2015-05/2017	James Henderson, PhD, University of Michigan - Michigan Medicine

### **Resident/House Officer**

09/2006-07/2009	Eric A. Singer, MA, MD, University of Rochester
09/2006-07/2009	Deep Trivedi, MD, University of Rochester
09/2006-07/2009	Dragan Golijanin, MD, University of Rochester
09/2006-07/2009	Angelo Cambio, MD, University of Rochester
09/2006-07/2009	Jennifer Rothschild, MD, University of Rochester
08/2009-07/2012	John Colen, MD, The Methodist Hospital/Baylor College of Medicine
08/2009-07/2012	Philip Ho, MD, The Methodist Hospital/Baylor College of Medicine
08/2009-07/2012	Robert Chan, MD, The Methodist Hospital/Baylor College of Medicine
08/2009-07/2012	Lambros Stamatakis, MD, The Methodist Hospital/Baylor College of Medicine
08/2009-07/2012	Ken Yun, MD, The Methodist Hospital/Baylor College of Medicine
09/2012-06/2017	Duncan Morhardt, MD, University of Michigan - Michigan Medicine
07/2013-06/2014	Matt Smith, MD, University of Michigan - Michigan Medicine
09/2013-06/2017	Ian McLaren, MD, University of Michigan - Michigan Medicine
07/2015-06/2018	Amy Luckenbaugh, MD, University of Michigan - Michigan Medicine
07/2015-06/2018	Amir Lebatschi, MD, University of Michigan - Michigan Medicine
07/2016-06/2020	Matthew Lee, MD, University of Michigan - Michigan Medicine
07/2016-06/2020	Christopher Russell, MD, University of Michigan - Michigan Medicine
07/2016-present	Udit Singhal, MD, University of Michigan - Michigan Medicine

### **Teaching Activity**

#### **National**

05/2004	Course Instructor - Modern Therapy of Muscle-Invasive Bladder Cancer; American Urological Association Annual Meeting; San Francisco, California
05/2013	Course Director - Prostate Cancer Biomarkers and Other Prediction Tools; American Urological Association Annual Meeting; San Diego, CA
06/2014-06/2015	American Urological Association Annual Basic Sciences Review Course - Prostate Cancer
07/2017	University of Alabama Gulf Coast Urology Seminar
07/2017	CME on the Fly Summer Urologic Seminar

#### **Institutional**

04/2006-06/2008	Pathology Graduate Seminar Lecturer on Inflammation and Carcinogenesis - University of Rochester School of Medicine,
-----------------	--

09/2006-07/2008	2nd Year Medical Student, DPT Course Lecturer on Prostate Cancer and Testicular Cancer - University of Rochester School of Medicine,
09/2006-07/2009	Urology Residency Program - University of Rochester School of Medicine
	Faculty Leader, Weekly Urology Grand Rounds
	Faculty Leader, Monthly Urology Journal Club
	Faculty Leader, Monthly Frank Resident Clinic Conference
	Faculty Coordinator/Lecturer, Faculty Lecture Series
01/2009-09/2012	Leader, Attending Rounds - The Methodist Hospital/Baylor College of Medicine
01/2009-09/2012	Urology Journal Club - The Methodist Hospital/Baylor College of Medicine
01/2009-09/2012	Faculty Presenter, Urology Grand Rounds - The Methodist Hospital/Baylor College of Medicine
09/2012-present	Faculty Presenter, Urology Grand Rounds, Journal Club, Departmental Morbidity & Mortality Conference - University of Michigan - Michigan Medicine

### **Dissertation Committees**

2013	Akash Kaushik, Integration of Metabolomics with Gene-Expression Data to Nominate Potential Biochemical Processes Associated with Castrate Resistant Prostate Cancer, Baylor College of Medicine; Houston, Texas, Biochemistry, Committee Member
2016	Klara Ternov, Assessing the Efficacy and Toxicity of Advanced Hormone Therapy in Metastatic Prostate Cancer., University of Copenhagen Herlev Hospital, Denmark, Urology, Committee Member

### **Committee and Administrative Services**

#### **Committee Services**

##### **International**

2017-present	Copenhagen-Michigan (CopMich) Collaboration, Co-Chair
--------------	---

##### **National**

2009-present	Southwest Oncology Group Study S0931 - EVEREST EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study, Study Co-Chair
2014-2016	Society of Urologic Oncology, Nominating Committee
2015	American Urological Association Research Grants Investigator Support Committee, Committee Member
2016	American Society of Clinical Oncology Scientific Program Committee, Genitourinary (Prostate) Cancer Committee Member
2017-2019	Society of Urologic Oncology Rapid Response Committee, Member

##### **Regional**

2018-present	P.C.U.P.S. Foundation, Board Member/Medical Director
--------------	--

##### **Institutional**

2006-2009	Cancer Committee - Wilmot Cancer Center, Strong Hospital, Member
2006-2009	GU Oncology Multi-Disciplinary Conference - Strong Hospital, Chair
2006-2009	Urology Residency Program - University of Rochester School of Medicine, Assistant Program Director
2008-2009	Urology Residency Education Committee - University of Rochester, Chair
2010-2012	Urology CMPI Committee - Houston Methodist Hospital, Chair
2012-2018	Graduate Education Committee, Department of Urology, University of Michigan, Ann Arbor, Michigan, Member

2012-2018	Urology Michigan, Department of Urology, University of Michigan, Ann Arbor, Michigan, Member
2012-present	Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, Chief
2012-present	Men of Michigan Prostate Cancer Research Fund, University of Michigan, Ann Arbor, Michigan, Chair
2013-2016	Cancer Research Committee, University of Michigan, Ann Arbor, Michigan, Member
2013-2018	Clinical Competency Committee, Department of Urology, University of Michigan, Ann Arbor, Michigan, Member
2013-present	GU Oncology Tumor Board, University of Michigan, Ann Arbor, Michigan, Faculty Lead
2013-present	Robotics Steering Committee, University of Michigan, Ann Arbor, Michigan, Member
2014-2015	Executive Committee, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, Member
2014-2015	University of Michigan Medical School, Ann Arbor, Michigan, Admissions Interviewer
2015-2021	Senior Clinical Leadership Committee, Department of Urology, University of Michigan, Ann Arbor, Michigan, Member
2015-present	Prostate Cancer Program, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, Co-Lead
2017-2018	Radiology Chair Search Committee, University of Michigan, Ann Arbor, Michigan, Member
2017-present	University of Michigan/Peking University Health Science Center Joint Institute Executive Committee, Member
2018-present	Rogel Cancer Center Planning Steering Committee, University of Michigan, Ann Arbor, Michigan, Member
2018-present	Rogel Cancer Center Reputation Management Committee, University of Michigan, Ann Arbor, Michigan, Member
2019-present	UMMG Board of Directors, University of Michigan, Ann Arbor, Michigan, Voting Member
2019	Dana Farber /Harvard Cancer Center SPORE External Advisory Board, Member
2019	Howard University College of Medicine External Advisory Board, Member
2019	University of Alabama Cancer Center External Advisory Board, Member
2019	Weill Cornell Medical College Tenure Review Subcommittee for Dr. Jim Hu, External Member
2020-present	UMMG Board Executive Committee, University of Michigan, Ann Arbor, Michigan, Voting Member
2020	Orthopaedic Chair Search Committee, University of Michigan, Ann Arbor, Michigan, Co-Chair
2021-2023	Contact Center, University of Michigan, Ann Arbor, Michigan, Chair Sponsor and Special Advisor to the Sr. Assoc Dean for Clinical Affairs/UMMG Executive Director
2022-2023	Executive Director of University of Michigan Medical Group, Search Committee, University of Michigan, Ann Arbor, Michigan, Co-Chair

## Visiting Professorships and Extramural Invited Presentations

### Visiting Professorships

02/2007	Roswell Park Cancer Institute, Department of Urology, February 2007, Buffalo, New York
03/2007	Ordway Research Institute, Inc., Cancer Center/SUNY Albany Medical Center, Department of Urology, March 2007, Albany, New York
02/2014	Rutgers, Cancer Institute of New Jersey, Department of Urology, February 2014, New Brunswick, New Jersey
07/2014	Brown University, Department of Urology, July 2014, Providence, Rhode Island
09/2014	Medical University of Vienna, Department of Urology, September 2014, Vienna, Austria
03/2015	University of Zurich, Department of Urology, March 2015, Zurich, Switzerland

10/2015	Swansea University Medical School, Department of Urology, October 2015, Wales, United Kingdom
10/2016	Weill Cornell Medical School, Department of Urology, October 2016, New York, New York
11/2016	Copenhagen University Hospital, Herlev Hospital Department of Urology, November 2016, Copenhagen, Denmark
04/2017	Icahn School of Medicine at Mount Sinai, Department of Urology, April 2017, New York, New York
01/2020	The Biology of Prostate Cancer Metastasis: Why Should We Care?, Stanford University, January 2020, Stanford, California
01/2020	Molecular Dissection of Prostate Cancer, Stanford University, January 2020, Stanford, California

### **Extramural Invited Presentations**

1. Pros and Cons of PSA Screening for Prostate Cancer, Veterans Administration Hospital System, December 2005, Rochester, New York
2. Emerging Insights into the Development of Prostate Cancer, American Cancer Society Man to Man Group, January 2006, Syracuse, New York
3. Department of Urology Grand Rounds, New York University School of Medicine, September 2006, New York, New York
4. Presenter - First Annual Prostate Cancer Forum, American Cancer Society, September 2006, Rochester, New York
5. Robotic Prostatectomy, American Cancer Society Man to Man Group, August 2007, Canandaigua, New York
6. Controversies in Prostate Cancer Management: Surgical Management, St. Agnes Medical Center Oncology Symposium, October 2007, Fresno, California
7. Robotic Prostatectomy for Prostate Cancer, Cayuga Medical Center, October 2007, Cayuga, New York
8. Radio Show Guest - Men's Health, WXXI 1370AM Radio Program hosted by Bob Smith, July 2008, Rochester, New York
9. TV Program Guest - Why Women Live Longer Than Men, Second Opinion TV Program, September 2008, WXXI from PBS
10. Presenter, Urologic Society of India National Meeting, February 2010, Agra, India
11. Moderator - Indian American, AUA Annual Meeting, Oncology Section, May 2012, Atlanta, Georgia
12. Invited Speaker - Center for Modeling Cancer Development, The Methodist Hospital Research Institute, January 2013, Houston, Texas
13. Presenter - Duncan Cancer Center Grand Rounds, Baylor College of Medicine, March 2013, Houston, Texas
14. Plenary Speaker - Rising Star Update, American Urological Association Annual Meeting, May 2013, San Diego, California
15. Panel Member - Biomarkers of Prostate Cancer Aggressiveness, Special Programs of Research Excellence (SPORE) - 14th Annual Meeting of the Society of Urologic Oncology, December 2013, Rockville, Maryland
16. Plenary Panelist - Prostate Cancer Tumor Board, Genitourinary Cancers Symposium, American Society of Clinical Oncology, January 2014, San Francisco, California
17. Prostate Cancer: What We Know, What We Don't Know and What We Need To Know, Resident Grand Rounds Case Presentation, Rutgers Cancer Institute of New Jersey, Department of Urology, February 2014, New Brunswick, New Jersey
18. Moderator and Speaker - Leveraging Metabolomic Strategies for CRPC, International Prostate Cancer SPORE Program Retreat, March 2014, Ft. Lauderdale, Florida
19. Metabolomic Strategies for Lethal Prostate Cancer, UCLA, April 2014, Los Angeles, California
20. Prostate Cancer: What We Know, What We Don't Know and What We Need To Know, Brown University, July 2014, Providence, Rhode Island
21. Leveraging Metabolomic Strategies for Lethal Prostate Cancer, Brown University, July 2014, Providence, Rhode Island

22. Invited speaker - Prostate Cancer, Chinese Urological Association Annual Prostate Cancer Meeting, September 2014, Shanghai, China
23. Metabolomics in Prostate Cancer, Urological Research Society Annual Meeting, September 2014, Munich, Germany
24. Prostate Cancer Biomarkers, Medical University of Vienna, Department of Urology, September 2014, Vienna, Austria
25. Invited Participant - Provocative Questions Workshop, National Cancer Institute, November 2014, Bethesda, Maryland
26. Invited Speaker - Prostate Cancer, Society for Basic Urologic Research Fall Symposium, November 2014, Dallas, Texas
27. Platelet Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling, University of Zurich, March 2015, Zurich, Switzerland
28. Moderator - Best Science From The Urologic Research Society, American Urological Association Annual Meeting, May 2015, New Orleans, Louisiana
29. Application of Personalized Medicine to Prostate Cancer, American Urological Association Annual Meeting, May 2015, New Orleans, Louisiana
30. Role For The Hexosamine Biosynthetic Pathway in Androgen Dependent Prostate Cancer, American Urological Association Annual Meeting, May 2015, New Orleans, Louisiana
31. Educational Talk: Cancer Support Community of Greater Ann Arbor - Prostate Cancer Support Group, University of Michigan - Michigan Medicine Comprehensive Cancer Center Community Outreach Program, September 2015, Ann Arbor, MI
32. Ann Arbor District Library Educational Talk: Prostate Cancer Screening Issues, University of Michigan - Michigan Medicine Comprehensive Cancer Center's Community Outreach Program, September 2015, Ann Arbor, Michigan
33. Prostate Cancer Biomarkers and Precision Medicine in Prostate Cancer, CopMich Urology Annual Symposium, November 2015, Copenhagen, Denmark
34. Characterizing and Targeting Altered Biochemical Pathways in Lethal Prostate Cancer, Medical University of Vienna, Department of Urology, November 2015, Vienna, Austria
35. Washtenaw Community College Educational Talk: Michigan Medicine Breast & Prostate Event, University of Michigan - Michigan Medicine Comprehensive Cancer Center Community Outreach Program, December 2015, Ann Arbor, MI
36. Next Generation Sequencing to Determine the Clonal Origin of Lymph Node Metastasis in Multifocal Prostate Cancer: Defining the Biologically Dominant Nodule, Medical University of Vienna, Department of Urology, December 2016, Vienna, Austria
37. Poster Session Chair - Improving Prostate Cancer Staging and Outcomes after Radical Prostatectomy, European Association of Urology Congress, March 2017, London, England
38. Poster Session Moderator - Prostate Cancer: Markers I, American Urological Association Annual Meeting, May 2017, Boston, Massachusetts
39. Discussion of Abstracts - Intensification of Therapy for Locally Advanced and Oligometastatic Disease, American Society of Clinical Oncology Annual Meeting, June 2017, Chicago, Illinois
40. Upper Urinary Tract Malignancies, Scandinavian Association of Urology (NUF) 31st Biennial Conference, June 2017, Odense, Denmark
41. Multimodal Treatment of Advanced Prostate Cancer. Where Do We Stand Today?, Scandinavian Association of Urology (NUF) 31st Biennial Conference, June 2017, Odense, Denmark
42. Molecular Dissection of Multifocal Prostate Cancer and Synchronous Lymph Node Metastasis: Implications for Tissue-based Prognostic Biomarkers, Scandinavian Association of Urology (NUF) 31st Biennial Conference, June 2017, Odense, Denmark
43. Surgical-Skills Training of Residents – Experiences from USA, Scandinavian Association of Urology (NUF) 31st Biennial Conference, June 2017, Odense, Denmark
44. Prostate Cancer Heterogeneity, Regional Prostate Cancer Meeting, Wuxi Second Hospital, July 2017, Wuxi, China
45. Prostate Cancer Heterogeneity, International Prostate Cancer Symposium & Inaugural World Congress of Robotic Urologic Oncology - Ichahn School of Medicine at Mount Sinai, September 2017, Manhattan, New York

46. Poster Session Moderator - Prostate Cancer: Localized Surgical Therapy III, American Urological Association Annual Meeting, May 2018, San Francisco, California
47. Restriction Spectrum Imaging of Metastatic Prostate Cancer, Coffey-Holden Prostate Cancer Academy Meeting - Luskin Center, University of California Los Angeles (UCLA), June 2018, Los Angeles, California
48. Session Chair - New Trials Update: What We Need to Know, European Multidisciplinary Congress on Urological Cancers, November 2018, Amsterdam, Netherlands
49. Why Some Patients Get Only Oligo-Metastatic Disease?, European Multidisciplinary Congress on Urological Cancers, November 2018, Amsterdam, Netherlands
50. Poster Session Moderator - Prostate Cancer: Detection & Screening II, American Urological Association Annual Meeting, May 2019, Chicago, Illinois
51. Department of Urology Grand Rounds, Weill Cornell (Virtual), June 2020, New York, New York

## Patents

### Granted

- |         |  |
|---------|--|
| 01/2012 | Chemically-Selective, Label Free, Microendoscopic System Based on Coherent Anti-Stokes Raman Scattering and Microelectromechanical Fiber Optic Probe, US 2012 /0010513 A1, Co-inventor, Submitted on 01/2011 |
| 01/2015 | Sustained Drug Delivery from Solid State Compositions with Nanochannel Membranes, US 2015/0032088 A1, Co-inventor, Submitted on 01/2013  |
| 11/2016 | Implantable Nanochannel Delivery Devices, WO 2016/187100 A1, Co-inventor, Submitted on 05/2015   |

## Bibliography

### Peer-Reviewed Journals and Publications

1. **Palapattu GS**, Bao S, Kumar TR, Matzuk MM: Transgenic Mouse Models for Tumor Suppressor Genes. *Cancer Detect Prev* 22(1): 75-86, 1998. PM9466053
2. Hu JC, **Palapattu GS**, Kattan MW, Scardino PT, Wheeler TM: The Association of Selected Pathological Features with Prostate Cancer in a Single-Needle Biopsy Accession. *Hum Pathol* 29(12): 1536-1538, 1998. PM9865844
3. Kumar TR, **Palapattu GS**, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM: Transgenic Models to Study Gonadotropin Function: The Role of Follicle-Stimulating Hormone in Gonadal Growth and Tumorigenesis. *Mol Endocrinol* 13(6): 851-865, 1999. PM10379885
4. **Palapattu GS**, Naitoh J, Belldgrun AS: Gene Therapy for Prostate Cancer. *New Perspectives on an Old Problem. Urol Clin North Am* 26(2): 353-363, ix, 1999. PM10361558
5. **Palapattu GS**, Shoskes DA: Resolution of the Chronic Pelvic Pain Syndrome After Renal Transplantation. *J Urol* 164(1): 127, 2000. PM10840443
6. **Palapattu GS**, Vasavada SP, Comiter CV, Raz, S: Urethral Diverticulum. *Urol Clin North Am* 8(1): 61-70, 2000.
7. Freedland SJ, Eilber KS, **Palapattu GS**, Rajfer J: Conservative Management of a Grade 4 Renal Laceration in a Child. *Rev Urol* 3(1): 40-41, 2001. PM16985689
8. **Palapattu GS**, Barbaric Z, Rajfer J: Acute Bilateral Renal Cortical Necrosis as a Cause of Postoperative Renal Failure. *Urology* 58(2): 281, 2001. PM11489723
9. Amara N, **Palapattu GS**, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE: Prostate Stem Cell Antigen is Overexpressed in Human Transitional Cell Carcinoma. *Cancer Res* 61(12): 4660-4665, 2001. PM11406532
10. **Palapattu GS**, Reiter RE: Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. *J Urol* 168(6): 2615-2623, 2002. PM12441996
11. **Palapattu GS**, Kristo B, Rajfer J: Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma. *Rev Urol* 4(4): 163-170, 2002. PM16985675
12. **Palapattu GS**, Kim HL, Belldgrun AS: Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC. *Rev Urol* 5(4): 232-234, 2003. PM16985843

13. **Palapattu GS**, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS: Collecting System Invasion in Renal Cell Carcinoma: Impact on Prognosis and Future Staging Strategies. *J Urol* 170(3): 768-772; discussion 772, 2003. PM12913694
14. **Palapattu GS**, Kim HL, Belldegrun AS: Lymph Node Dissection in Patients with Kidney Cancer: When is it Indicated? *Rev Urol* 5(3): 196-199, 2003. PM16985641/PMC1473016
15. Bastian PJ, Yegnasubramanian S, **Palapattu GS**, Rogers CG, Lin X, De Marzo AM, Nelson WG: Molecular Biomarker in Prostate Cancer: The Role of CpG Island Hypermethylation. *Eur Urol* 46(6): 698-708, 2004. PM15548435
16. **Palapattu GS**, Bastian PJ, Slavney PR, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J, Schoenberg MP: Preoperative Somatic Symptoms are Associated with Disease Progression in Patients with Bladder Carcinoma After Cystectomy. *Cancer* 101(10): 2209-2213, 2004. PM15476276
17. **Palapattu GS**, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J, Schoenberg M: Assessment of Perioperative Psychological Distress in Patients Undergoing Radical Cystectomy for Bladder Cancer. *J Urol* 172(5 Pt 1): 1814-1817, 2004. PM15540727
18. **Palapattu GS**, Allaf ME, Trock BJ, Epstein JI, Walsh PC: Prostate Specific Antigen Progression in Men with Lymph Node Metastases Following Radical Prostatectomy: Results of Long-Term Followup. *J Urol* 172(5 Pt 1): 1860-1864, 2004. PM15540739
19. **Palapattu GS**, Bloom DA, Smith RB, Boxer RJ: Willard E. Goodwin: Educator, Innovator and Pioneer. *J Urol* 172(1): 40-44, 2004. PM15201733
20. Allaf ME, **Palapattu GS**, Trock BJ, Carter HB, Walsh PC: Anatomical Extent of Lymph Node Dissection: Impact on Men with Clinically Localized Prostate Cancer. *J Urol* 172(5 Pt 1): 1840-1844, 2004. PM15540734
21. Lotan Y, Gupta A, Shariat SF, **Palapattu GS**, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI: Lymphovascular Invasion is Independently Associated with Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients with Negative Lymph Nodes at Radical Cystectomy. *J Clin Oncol* 23(27): 6533-6539, 2005. PM16116151
22. **Palapattu GS**, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG: Prostate Carcinogenesis and Inflammation: Emerging Insights. *Carcinogenesis* 26(7): 1170-1181, 2005. PM15498784
23. Bastian PJ, **Palapattu GS**, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG: Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. *Clin Cancer Res* 11(11): 4037-4043, 2005. PM15930338
24. **Palapattu GS**, DeMarzo AM, Nelson WG: The Case for the Role of Chronic Inflammation in the Development of Prostate Cancer. *North American Pharmacotherapy* 1: 100-103, 2005.
25. **Palapattu GS**, Freedland SJ: Primary Treatment for Localized Prostate Cancer. *Med Lett* 37: 63-68, 2005.
26. Karakiewicz PI, Shariat SF, **Palapattu GS**, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP: Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. *Eur Urol* 50(6): 1254-1260; discussion 1261-1262, 2006. PM16831511
27. Shariat SF, **Palapattu GS**, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Characteristics and Outcomes of Patients with Carcinoma in Situ Only at Radical Cystectomy. *Urology* 68(3): 538-542, 2006. PM16979748
28. Karakiewicz PI, Shariat SF, **Palapattu GS**, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP: Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. *J Urol* 176(4 Pt 1): 1354-1361; discussion 1361-1362, 2006. PM16952631
29. **Palapattu GS**, Meeker A, Harris T, Collector MI, Sharkis SJ, DeMarzo AM, Warlick C, Drake CG, Nelson WG: Epithelial Architectural Destruction is Necessary for Bone Marrow Derived Cell Contribution to Regenerating Prostate Epithelium. *J Urol* 176(2): 813-818, 2006. PM16813953
30. Rogers CG, **Palapattu GS**, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP: Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. *J Urol* 175(6): 2048-2053; discussion 2053, 2006. PM16697800



31. **Palapattu GS**, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP: Bladder Cancer Research Consortium: Cancer Specific Outcomes in Patients with pT0 Disease Following Radical Cystectomy. *J Urol* 175(5): 1645-1649; discussion 1649, 2006. PM16600721
32. **Palapattu GS**, Messing EM: Do Prostate Cancer Patients at Risk of Pelvic Lymph-Node Metastasis Benefit from Pelvic Radiation? *Nat Clin Pract Urol* 3(5): 258-259, 2006. PM16691238
33. Shariat SF, Karakiewicz PI, **Palapattu GS**, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP: Nomograms Provide Improved Accuracy for Predicting Survival After Radical Cystectomy. *Clin Cancer Res* 12(22): 6663-6676, 2006. PM17121885
34. Shariat SF, Karakiewicz PI, **Palapattu GS**, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series from the Bladder Cancer Research Consortium. *J Urol* 176(6): 2414-2422, 2006. PM17085118
35. Nielsen ME, Bastian PJ, **Palapattu GS**, Trock BJ, Schoenberg MP, Chan T, Rogers CG: Recurrence-Free Survival After Radical Cystectomy of Patients Downstaged by Transurethral Resection. *Urology* 70(6): 1091-1095, 2007. PM18158024
36. Nielsen ME, **Palapattu GS**, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, Shariat SF: A Delay in Radical Cystectomy of >3 Months is Not Associated with a Worse Clinical Outcome. *Br J Urol* 100(5): 1015-1020, 2007. PM17784888
37. Bastian PJ, **Palapattu GS**, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG: Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. *Clin Cancer Res* 13(18 Pt 1): 5361-5367, 2007. PM17875764
38. Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, **Palapattu GS**: Bladder Cancer Research Consortium: Advanced Age is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. *Eur Urol* 51(3): 699-706; discussion 706-708, 2007. PM17113703
39. Shariat SF, **Palapattu GS**, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Discrepancy Between Clinical and Pathologic Stage: Impact on Prognosis After Radical Cystectomy. *Eur Urol* 51(1): 137-149; discussion 149-151, 2007. PM16793197
40. Shariat SF, **Palapattu GS**, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Concomitant Carcinoma in Situ is a Feature of Aggressive Disease in Patients with Organ-Confined TCC at Radical Cystectomy. *Eur Urol* 51(1): 152-160, 2007. PM17011114
41. Singer EA, Penson DF, **Palapattu GS**: PSA Screening and Elderly Men. *JAMA* 297(9): 949; author reply 949-950, 2007. PM17341705
42. Guzzo TJ, Rogers CG, Deng CY, Bivalacqua TJ, **Palapattu GS**, Bastian PJ, Eisenberger MA, Schoenberg MP, Gonzalgo ML: Outcomes of Patients After Aborted Radical Cystectomy for Intraoperative Findings of Metastatic Disease. *BJU Int* 102(11): 1539-1543, 2008. PM18727617
43. Singer EA, **Palapattu GS**, van Wijngaarden E: Prostate-Specific Antigen Levels in Relation to Consumption of Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen: Results from the 2001-2002 National Health and Nutrition Examination Survey. *Cancer* 113(8): 2053-2057, 2008. PM18780337
44. Walz J, Shariat SF, Suardi N, Perrotte P, Lotan Y, **Palapattu GS**, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI: Adjuvant Chemotherapy for Bladder Cancer does not Alter Cancer-Specific Survival After Cystectomy in a Matched Case-Control Study. *BJU Int* 101(11): 1356-1361, 2008. PM18454792
45. Marshall JS, Cardin AL, **Palapattu GS**: A Simple Inexpensive Snare for Manipulation of Intravesical Foreign Bodies. *Can J Urol* 15(1): 3936-3938, 2008. PM18304410
46. Bastian PJ, **Palapattu GS**, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG: CpG Island Hypermethylation Profile in the Serum of Men with Clinically Localized and Hormone Refractory Metastatic Prostate Cancer. *J Urol* 179(2): 529-534; discussion 534-535, 2008. PM18076941
47. Bastian PJ, Hutterer GC, Shariat SF, Rogers CG, **Palapattu GS**, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI: Bladder Cancer Research Consortium: Macroscopic, But Not Microscopic, Perivesical Fat Invasion at Radical Cystectomy is an Adverse Predictor of Recurrence and Survival. *BJU Int* 101(4): 450-454, 2008. PM17850359

48. van Wijngaarden E, Singer EA, **Palapattu GS**: Prostate-Specific Antigen Levels in Relation to Cadmium Exposure and Zinc Intake: Results from the 2001-2002 National Health and Nutrition Examination Survey. *The Prostate* 68(2): 122-128, 2008. PM18044729
49. Simon RA, di Sant'agnese PA, **Palapattu GS**, Singer EA, Candelario GD, Huang J, Yao JL: Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Sarcomatoid Differentiation. *Int J Clin Exp Pathol* 1(2): 180-184, 2008. PM18784804
50. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, **Palapattu GS**, Cote RJ, Sagalowsky AI, Lotan Y: Multiple Biomarkers Improve Prediction of Bladder Cancer Recurrence and Mortality in Patients Undergoing Cystectomy. *Cancer* 112(2): 315-325, 2008. PM18008359
51. Gupta A, Lotan Y, Bastian PJ, **Palapattu GS**, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, Shariat SF, Bladder Cancer Research Consortium: Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy. *Urology* 71(2): 302-307, 2008. PM18308108
52. Golijanin D, **Palapattu GS**: Editorial Comment - Bladder and Urethral Sphincter Function After Radical Retropubic Prostatectomy: A Prospective Long-Term Study. *Eur Urol* 54(3): 664, 2008. PM18006211
53. Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, **Palapattu GS**, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G: Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. *J Urol* 182(2): 459-465; discussion 465, 2009. PM19524971
54. Capitanio U, Suardi N, Shariat SF, Lotan Y, **Palapattu GS**, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI: Assessing the Minimum Number of Lymph Nodes Needed at Radical Cystectomy in Patients with Bladder Cancer. *BJU Int* 103(10): 1359-1362, 2009. PM19076140
55. Simon RA, di Sant'Agnes PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, **Palapattu GS**, Wei J, Huang J: CD44 Expression is a Feature of Prostatic Small Cell Carcinoma and Distinguishes It from Its Mimickers. *Hum Pathol* 40(2): 252-258, 2009. PM18835619
56. **Palapattu GS**, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J: Selective Expression of CD44, a Putative Prostate Cancer Stem Cell Marker, in Neuroendocrine Tumor Cells of Human Prostate Cancer. *The Prostate* 69(7): 787-798, 2009. PM19189306
57. Mener DJ, Cambio A, Stoddard DG, Martin BA, **Palapattu GS**: The Impact of HMG-CoA Reductase Therapy on Serum PSA. *The Prostate* 70(6): 608-615, 2010. PM19998369
58. **Palapattu GS**, Singer EA, Messing EM: Controversies Surrounding Lymph Node Dissection for Prostate Cancer. *Urol Clin North Am* 37(1): 57-65, table of contents, 2010. PM20152520
59. Prasad MM, Prasad SM, Hevelone ND, Gu X, Weinberg AC, Lipsitz SR, **Palapattu GS**, Hu JC: Utilization of Pharmacotherapy for Erectile Dysfunction Following Treatment for Prostate Cancer. *JSM* 7(3): 1062-1073, 2010. PM20059662
60. Sonpavde G, **Palapattu GS**: Neoadjuvant Therapy Preceding Prostatectomy for Prostate Cancer: Rationale and Current Trials. *Expert Rev Anticancer Ther* 10(3): 439-450, 2010. PM20214524
61. Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, **Palapattu GS**: A Novel in Vitro Assay of Tumor-Initiating Cells in Xenograft Prostate Tumors. *The Prostate* 70(13): 1379-1387, 2010. PM20687210
62. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, **Palapattu GS**, Lotan Y, Weizer AZ, Terris MK, Shariat SF, Michailidis G, Sreekumar A: Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. *Cancer Res* 71(24): 7376-7386, 2011. PM21990318
63. Gao L, Zhou H, Thrall MJ, Li F, Yang Y, Wang Z, Luo P, Wong KK, **Palapattu GS\***, Wong ST \*co-corresponding author: Label-Free High-Resolution Imaging of Prostate Glands and Cavernous Nerves Using Coherent Anti-Stokes Raman Scattering Microscopy. *Biomed Opt Express* 2(4): 915-926, 2011. PM21483613
64. Putluri N, Shojaie A, Vasu VT, Nalluri S, Vareed SK, Putluri V, Vivekanandan-Giri A, Byun J, Pennathur S, Sana TR, Fischer SM, **Palapattu GS**, Creighton CJ, Michailidis G, Sreekumar A: Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells. *PloS One* 6(7): e21417, 2011. PM21789170
65. Ulmer WD, Prasad SM, Kowalczyk KJ, Gu X, Dodgion C, Lipsitz S, **Palapattu GS**, Choueiri TK, Hu JC: Factors Associated with the Adoption of Minimally Invasive Radical Prostatectomy in the United States. *J Urol* 188(3): 775-780, 2012. PM22818134

66. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, **Palapattu GS**, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG: The PSA(-/lo) Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells That Resist Castration. *Cell Stem Cell* 10(5): 556-569, 2012. PM22560078
67. Sih J, Bansal SS, Filipini S, Ferrati S, Raghuwansi K, Zabre E, Nicolov E, Fine D, Ferrari M, **Palapattu GS**, Grattoni A: Characterization of Nanochannel Delivery Membrane Systems for the Sustained Release of Resveratrol and Atorvastatin: New Perspectives on Promoting Heart Health. *Anal Bioanal Chem* 405(5): 1547-1557, 2013. PM23090650
68. Sanchez C, Chan R, Bajgain P, Rambally S, **Palapattu GS**, Mims M, Rooney CM, Leen AM, Brenner MK, Vera JF: Combining T-Cell Immunotherapy and Anti-Androgen Therapy for Prostate Cancer. *Prostate Cancer and Prostatic Diseases* 16(2): 123-131, 2013. PM23295316
69. Khanna A, Hu JC, Gu X, Nguyen PL, Lipsitz S, **Palapattu GS**: Certificate of Need Programs, Intensity Modulated Radiation Therapy Use and the Cost of Prostate Cancer Care. *J Urol* 189(1): 75-79, 2013. PM23164382
70. Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, **Palapattu GS**, Michailidis G, Sreekumar A: Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer. *J Proteome Res* 13(2): 1088-1100, 2013. PM24359151
71. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, **Palapattu GS**, Kunju L, Mehra R, Sandler H, Feng FY: Larger Maximum Tumor Diameter at Radical Prostatectomy is Associated with Increased Biochemical Failure, Metastasis, and Death from Prostate Cancer After Salvage Radiation for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 87(2): 275-281, 2013. PM23886418
72. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrot M, Sandler HM, Morgan TM, **Palapattu GS**, Hamstra DA, Feng FY: A Prostate-Specific Antigen Doubling Time of <6 Months is Prognostic for Metastasis and Prostate Cancer-Specific Death for Patients Receiving Salvage Radiation Therapy Post Radical Prostatectomy. *Radiat Oncol* 8: 170, 2013. PM23835115
73. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, **Palapattu GS**, Kunju LP, Mehra R, Feng FY: Gleason Pattern 5 is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy. *Cancer* 119(18): 3287-3294, 2013. PM23821578
74. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, **Palapattu GS**, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM: The Role of Sarcosine Metabolism in Prostate Cancer Progression. *Neoplasia* 15(5): 491-501, 2013. PM23633921
75. Ferrati S, Fine D, You J, De Rosa E, Hudson L, Zabre E, Hosali S, Zhang L, Hickman C, Sunder Bansal S, Cordero-Reyes AM, Geninatti T, Sih J, Goodall R, **Palapattu GS**, Kloc M, Ghobrial RM, Ferrari M, Grattoni A: Leveraging Nanochannels for Universal, Zero-Order Drug Delivery in Vivo. *J Control Release* 172(3): 1011-1019, 2013. PM24095805
76. Bansal SS, Celia C, Ferrati S, Zabre E, Ferrari M, **Palapattu GS**, Grattoni A: Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations. *Curr Drug Targets* 14(9): 1061-1069, 2013. PM23721184
77. Wittmann D, Carolan M, Given B, Skolarus TA, An L, **Palapattu GS**, Montie JE: Exploring the Role of the Partner in Couples' Sexual Recovery After Surgery for Prostate Cancer. *Support Care Cancer* 22(9): 2509-2515, 2014. PM24728619
78. Warrick JI, Tsodikov A, Kunju LP, Chinnaiyan AM, **Palapattu GS**, Morgan TM, Alva A, Tomlins S, Wu A, Montgomery JS, Hafez KS, Wolf JS, Weizer AZ, Mehra R: Papillary Renal Cell Carcinoma Revisited: A Comprehensive Histomorphologic Study with Outcome Correlations. *Hum Pathol* 45(6): 1139-1146, 2014. PM24767860
79. Kozminski MA, **Palapattu GS**, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng FY, Wood DP, Kunju LP, Morgan TM: Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men with Prostate Cancer. *Urology* 84(2): 373-378, 2014. PM24958484
80. McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, **Palapattu GS**, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R: HRAS Mutations Are Frequent in Inverted Urothelial Neoplasms. *Hum Pathol* 45(9): 1957-1965, 2014. PM25097040
81. Turcu AF, Rege J, Chomic R, Liu J, Nishimoto HK, Else T, Moraitis AG, **Palapattu GS**, Rainey WE, Auchus RJ: Profiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency. *J Clin Endocrinol Metab* 100(6): 1023, 2015. PM25850025

82. Udager AM, Pan J, Magers MJ, **Palapattu GS**, Morgan TM, Montgomery JS, Weizer AZ, Hafez KS, Miller DC, Wolf JS Jr, McHugh JB, Chinnaiyan AM, Dhanasekaran SM, Mehra R: Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. *Am J Surg Pathol* 39(4): 549-557, 2015. PM25602792
83. Glazer DI, Davenport MS, Khalatbari S, Cohan RH, Ellis JH, Caoili EM, Stein EB, Childress JC, Masch WR, Brown JM, Mollard BJ, Montgomery JS, **Palapattu GS**, Francis IR: Mass-Like Peripheral Zone Enhancement on CT is Predictive of Higher-Grade (Gleason 4 + 3 and Higher) Prostate Cancer. *Abdom Imaging* 40(3): 560-570, 2015. PM25193787
84. Ferrati S, Nicolov E, Bansal S, Zabre E, Geninatti T, Ziemys A, Hudson L, Ferrari M, Goodall R, Khera M, **Palapattu GS**, Grattoni A: Delivering Enhanced Testosterone Replacement Therapy Through Nanochannels. *Adv Healthc Mater* 4(3): 446-451, 2015. PM25274059
85. Wittmann D, Carolan M, Given B, Skolarus TA, Crossley H, An L, **Palapattu GS**, Clark P, Montie JE: What Couples Say About Their Recovery of Sexual Intimacy After Prostatectomy: Toward the Development of a Conceptual Model of Couples' Sexual Recovery After Surgery for Prostate Cancer. *JSM* 12(2): 494-504, 2015. PM25358901
86. Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, **Palapattu GS**, Jiang H, Mehra R: Clinicopathologic Characteristics of Anterior Prostate Cancer (APC), Including Correlation with Previous Biopsy Pathology. *Med Oncol* 32(11): 249, 2015. PM26442515
87. Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, **Palapattu GS**: Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. *Neoplasia* 17(6): 490-496, 2015. PM26152357
88. Morgan T, **Palapattu GS**, Wei J: Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers. *Curr Urol Rep* 16(9): 63, 2015. PM26169584
89. Ferrati S, Nicolov E, Zabre E, Geninatti T, Shirkey BA, Hudson L, Hosali S, Crawley M, Khera M, **Palapattu GS**, Grattoni A: The Nanochannel Delivery System for Constant Testosterone Replacement Therapy. *JSM* 12(6): 1375-1380, 2015. PM25930087
90. Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng FY, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, **Palapattu GS**, Mehra R: Impact of Tertiary Gleason Pattern 5 on Prostate Cancer Aggressiveness: Lessons from a Contemporary Single Institution Radical Prostatectomy Series. *Asian J Urol* 2(1): 53-58, 2015. PM29264120/PMC5730694
91. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, **Palapattu GS**, Hamstra DA, Feng FY: Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. *Eur Urol* 69(1): 50-57, 2016. PM26004800
92. Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, **Palapattu GS**, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr: Age, Gender and R.E.N.A.L. Nephrometry Score Do Not Improve the Accuracy of a Risk Stratification Algorithm Based on Percutaneous Renal Mass Biopsy and Mass Size for Assigning Surveillance Versus Treatment of Renal Tumors. *J Urol* 195(3): 574-580, 2016. PM26523883
93. Paich K, Dunn R, Skolarus T, Montie J, Hollenbeck B, **Palapattu GS**, Wood D Jr, Mitchell S, Hola V, Erickson K, Shifferd J, Wittmann D: Preparing Patients and Partners for Recovery from the Side Effects of Prostate Cancer Surgery: A Group Approach. *Urology* Feb(88): 36-42, 2016. PM26541826
94. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, **Palapattu GS**, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM: Standardizing the Definition of Adverse Pathology for Lower Risk Men Undergoing Radical Prostatectomy. *Urol Oncol* 34(9): 415.e 1-6, 2016. PM27140065
95. Spratt DE, Cole AI, **Palapattu GS**, Weizer AZ, Jackson WC, Montgomery JS, Dess R, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM: Independent Surgical Validation of the New Prostate Cancer Grade Grouping System. *BJU Int* March: Online, 2016. PM27009882
96. Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, **Palapattu GS**, Mehra R, Morgan TM, Feng FY: Independent Validation of the Prognostic Capacity of the ISUP Prostate Cancer Grade Grouping System for Radiation Treated Patients with Long-Term Follow-Up. *Prostate Cancer Prostatic Dis* 19(3): 292-297, 2016. PM27215611

97. Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, **Palapattu GS**, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R: Frequent PD-L1 Expression in Primary and Metastatic Penile Squamous Cell Carcinoma: Potential Opportunities for Immunotherapeutic Approaches. *Ann Oncol May: Online*, 2016. PM27217541
98. Cole AI, Morgan TM, Spratt DE, **Palapattu GS**, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R: Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. *J Urol* 196(2): 405-411, 2016. PM26920466
99. Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, **Palapattu GS**, Michailidis G, Sreekumar A: Inhibition of the Hexosamine Biosynthetic Pathway Promotes Castration-Resistant Prostate Cancer. *Nat Commun* 7: 11612, 2016. PM27194471/PMC4874037
100. Alderman MA, Daignault S, Wolf JS Jr, **Palapattu GS**, Weizer AZ, Hafez KS, Kunju LP, Wu AJ: Categorizing Renal Oncocytic Neoplasms on Core Needle Biopsy: A Morphologic and Immunophenotypic Study of 144 Cases with Clinical Follow-Up. *Hum Pathol* 55: 1-10, 2016. PM27085554
101. **Palapattu GS**: Commentary on "AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan - Michigan Medicine, MI. *N Engl J Med* 2014; 371(11):1028-38. *Urol Oncol* 34(11): 520, 2016. PM26964769
102. Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, **Palapattu GS**, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS Jr: Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Versus Malignant Disease and Low- Versus High-Risk Renal Tumors. *Urology* 96: 87-92, 2016. PM27262393
103. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, **Palapattu GS**, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM: Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. *Neoplasia* 18(1): 1-9, 2016. PM26806347/PMC4735600
104. **Palapattu GS**: Parsing Multi-Omic Data to Understand Urothelial Cell Carcinoma Progression. *J Urol* 195 (6): 1645, 2016. PM26946160
105. Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL, Hawken S, Krishnan N, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, **Palapattu GS**, Weizer AZ, Wolf JS Jr: Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence our Decision? *Urology* 98: 88-96, 2016. PM27450936
106. Mehra R, Vats P, Cieslik M, Cao X, Su F, Shukla S, Udager AM, Wang R, Pan J, Kasaian K, Lonigro R, Siddiqui J, Premkumar K, **Palapattu GS**, Weizer A, Hafez KS, Wolf JS Jr, Sangoi AR, Trpkov K, Osunkoya AO, Zhou M, Giannico G, McKenney JK, Dhanasekaran SM, Chinnaiyan AM: Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. *Cancer Discov* 6(11): 1258-1266, 2016. PM27604489/PMC5096979
107. Hawken SR, Krishnan NK, Ambani SN, Montgomery JS, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Kutikov A, **Palapattu GS**, Weizer AZ, Stuart Wolf J, Morgan TM: Effect of Delayed Resection After Initial Surveillance and Tumor Growth Rate on Final Surgical Pathology in Patients with Small Renal Masses (SRMs). *Urol Oncol* 34(11): 486.e9-486.e15, 2016. PM27687544
108. Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, **Palapattu GS**, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R: Programmed Death-Ligand 1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus* 3(4-5): 502-509, 2016. PM28753826
109. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, **Palapattu GS**, Feng FY, Nguyen PL: Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. *Eur Urol Focus* 2(5): 532-539, 2016. PM28723519
110. **Palapattu GS**, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS: Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. *Clin Cancer Res* 23(4): 985-991, 2017. PM28031426/PMC5315613

111. Østergren P, Salami SS, Udager A, Sønksen J, Ohl D, **Palapattu GS**: A Rare Case of Bilateral Synchronous Spermatocytic Tumours in a Young Man Seeking Fertility Preservation. *Scand J Urol* 51(1): 78-80, 2017. PM27809692
112. Osawa T, Ambani SN, Olugbade K Jr, Skolarus TA, Weizer AZ, Montgomery JS, He C, Hafez KS, Hollenbeck BK, Lee CT, Montie JE, **Palapattu GS**, Morgan TM: Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. *Urology* 102: 92-99, 2017. PM28013038
113. Davenport MS, Hu EM, Smith AD, Chandarana H, Hafez K, **Palapattu GS**, Stuart Wolf J Jr, Silverman SG, Society of Abdominal Radiology Disease Focused Panel on Renal Cell Carcinoma: Reporting Standards for the Imaging-Based Diagnosis of Renal Masses on CT and MRI: A National Survey of Academic Abdominal Radiologists and Urologists. *Abdom Radiol (NY)* 42(4): 1229-1240, 2017. PM27878338
114. Salami SS, George AK, Montgomery JS, Morgan TM, **Palapattu GS**: Diagnostic Accuracy of the PROMIS Study. *Lancet* 390(10092): 362, 2017. PM28745602
115. Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, **Palapattu GS**, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE: Anatomical Patterns of Recurrence Following Biochemical Relapse After Post-Prostatectomy Salvage Radiation Therapy: A Multi-Institutional Study. *BJU Int* Epub ahead of print: Online, 2017. PM28139024
116. **Palapattu GS**: Genomic Tests Should Be Used to Help Guide Treatment of Prostate Cancer: Yes. *J Urol* 198(2): 265-266, 2017. PM28629664
117. Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, **Palapattu GS**, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ: Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. *Urology* 117: 95-100, 2018. PM29678662
118. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, **Palapattu GS**, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM: Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. *Mol Cancer Res* 16(4): 643-654, 2018. PM29453313/PMC5882567
119. Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, **Palapattu GS**: Transcriptomic Heterogeneity in Multifocal Prostate Cancer. *JCI Insight* 3(21): Online, 2018. PM30385730/PMC6238741
120. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, **Palapattu GS**, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE: Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. *Eur Urol* Epub ahead of print: online, 2018. PM29306514
121. Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, **Palapattu GS**, Wilding G, Droller M, Trump D: A Festschrift in Honor of Edward M. Messing, MD, FACS. *Bladder Cancer* 4(Suppl 1): S1-S43, 2018. PM30443561/PMC6226303
122. Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, **Palapattu GS**, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA: Association of ERG/PTEN Status with Biochemical Recurrence after Radical Prostatectomy for Clinically Localized Prostate Cancer. *Med Oncol* 35(12): 152, 2018. PM30291535
123. Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, **Palapattu GS**, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R: Clinical Utility and Concordance of Upper Urinary Tract Cytology and Biopsy in Predicting Clinicopathologic Features of Upper Urinary Tract Urothelial Carcinoma. *Hum Pathol* ePub ahead of print: Online, 2018. PM30537495
124. Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmboos P, Tamura S, Lazo de la Vega L, **Palapattu GS**, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA: Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. *Eur Urol* Epub ahead of print: online, 2018. PM30033047

125. Spratt DE, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, **Palapattu GS**, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R: Detailed Pathologic Analysis on the Co-Occurrence of Non-Seminomatous Germ Cell Tumor Subtypes in Matched Orchiectomy and Retroperitoneal Lymph Node Dissections. *Med Oncol* 35(3): 21, 2018. PM29387987
126. Salami SS, Singhal U, Spratt DE, **Palapattu GS**, Hollenbeck BK, Schonhoft JD, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Tomlins SA, Dittamore R, Feng FY, Morgan TM: Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. *JCO Precis Oncol* 3(3): 1-9, 2019. PM32832835/PMC7440257
127. Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, Spratt DE, Reichert Z, **Palapattu GS**, Taichman RS, Tomlins SA, Morgan TM: Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. *Neoplasia* 21(8): 802-809, 2019. PM31276932
128. Synold TW, Plets M, Tangen CM, Heath EI, **Palapattu GS**, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW: Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). *Kidney Cancer* 3(2): 111-118, 2019. PM31763512 /PMC6864417
129. Kvorning Ternov K, Sønksen J, Fode M, Lindberg H, Kistorp CM, Bisbjerg R, **Palapattu GS**, Østergren PB: Fatigue, Quality of Life and Metabolic Changes in Men Treated with First-Line Enzalutamide Versus Abiraterone Plus Prednisolone for Metastatic Castration-Resistant Prostate Cancer (HEAT): A Randomised Rial Protocol. *BMJ Open* 9(9): e030218, 2019. PM31511288/PMC6747677
130. Salami SS, Kaplan JB, Nallandhighal S, Takhar M, Tosoian JJ, Lee M, Yoon J, Hovelson DH, Plouffe KR, Kaffenberger SD, Schaeffer EM, Karnes RJ, Lotan TL, Morgan TM, George AK, Montgomery JS, Davenport MS, You S, Tomlins SA, Curci NE, Kim HL, Spratt DE, Udager AM, **Palapattu GS**: Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. *JCO Precis Oncol* 3: 1-12, 2019. PM32914029/PMC7446477
131. Lee GT, Rosenfeld JA, Kim WT, Kwon YS, **Palapattu GS**, Mehra R, Kim WJ, Kim IY: TCF4 Induces Enzalutamide Resistance via Neuroendocrine Differentiation in Prostate Cancer. *PLoS One* 14(9): e0213488, 2019. PM31536510/PMC6752758
132. Kennedy JM, Wang X, Plouffe KR, Dhanasekaran SM, Hafez K, **Palapattu GS**, Else T, Weizer AZ, Morgan TM, Spratt DE, Davenport MS, Chinnaiyan AM, Udager AM, Mehra R: Clinical and Morphologic Review of 60 Hereditary Renal Tumors from 30 Hereditary Renal Cell Carcinoma Syndrome Patients: Lessons from a Contemporary Single Institution Series. *Med Oncol* 36(9): 74, 2019. PM31332543
133. Abdulfatah E, Kennedy JM, Hafez K, Davenport MS, Xiao H, Weizer AZ, **Palapattu GS**, Morgan TM, Mannan R, Wang XM, Dhanasekaran SM, Kaffenberger SD, Spratt DE, Kunju L, Wu A, Lew M, Udager AM, Chinnaiyan AM, Mehra R: Clinicopathological Characterization of Renal Cell Carcinoma in Young Adults: A Contemporary Update and Review of Literature. *Histopathology* epub ahead of print: in print, 2019. PM31872452
134. Gohlke JH, Lloyd SM, Basu S, Putluri V, Vareed SK, Rasaily U, Piyarathna DWB, Fuentes H, Rajendiran TM, Dorsey TH, Ambati CR, Sonavane R, Karanam B, Bhowmik SK, Kittles R, Ambs S, Mims MP, Ittmann M, Jones JA, **Palapattu GS**, Putluri N, Michailidis G, Sreekumar A: Methionine-Homocysteine Pathway in African-American Prostate Cancer. *JNCI Cancer Spectr* 3(2): pkz019, 2019. PM31360899 /PMC6489686
135. Wang Y, Singhal U, Qiao Y, Kasputis T, Chung JS, Zhao H, Chammaa F, Belardo JA, Roth TM, Zhang H, Zaslavsky AB, **Palapattu GS**, Pienta KJ, Chinnaiyan AM, Taichman RS, Cackowski FC, Morgan TM: Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. *Transl Oncol* 13(4): 100747, 2020. PM32217460/PMC7109463
136. Kaplan MH, Contreras-Galindo R, Jiagge E, Merajver SD, Newman L, Bigman G, Dosik MH, **Palapattu GS**, Siddiqui J, Chinnaiyan AM, Adebamowo S, Adebamowo C: Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer? *Infect Agent Cancer* 15: 19, 2020. PM32165916/PMC7060579
137. Zaslavsky AB, Adams MP, Cao X, Maj T, Choi JE, Stangl-Kremser J, Patel S, Putelo A, Lee SK, Nallandhighal S, Kasputis A, Alva A, Lew M, Qin A, Mehra R, Morgan TM, Salami SS, Reichert Z, Udager A, Zou W, **Palapattu GS**: Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. *Sci Rep* 10(1): 19296, 2020. PM33168847/PMC7652857

138. Salami SS, Tosoian JJ, Nallandhighal S, Jones TA Jr, Brockman S, Elkhoury FF, Bazzi S, Plouffe KR, Siddiqui J, Liu CJ, Kunju LP, Morgan TM, Natarajan S, Boonstra PS, Sumida L, Tomlins SA, Udager AM, Sisk AE Jr, Marks LS, **Palapattu GS**: Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. *Eur Urol* July 2020: Published Online, 2020. PM32631746
139. Andino JJ, Dupree JM, Jensen CFS, **Palapattu GS**, Sønksen J, Wittmann D: COVID and CopMich: comparing and contrasting COVID-19 experiences in the USA and Scandinavia. *Nat Rev Urol* July 2020: Published Online, 2020. PM32632304/PMC7338095
140. Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, **Palapattu GS**, Wei JT, Niknafs YS, Chinnaiyan AM: Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. *J Urol* 205(3): 732-739, 2021. PM33080150
141. Stensland KD, Kaffenberger SD, George AK, Morgan TM, Miller DC, Salami SS, Dunn RL, Palapattu GS, Montgomery JS, Hollenbeck BK, Skolarus TA: Prostate cancer clinical trial completion: The role of geography. *Contemp Clin Trials* 111: 106600, 2021. PM34673273/PMC8908357
142. Ternov KK, Nolsøe AB, Bratt O, Fode M, Lindberg H, Kistorp C, **Palapattu G**, Klausen TW, Sønksen J, Østergren PB: Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis* 2021-04-05: 1365-7852, 2021. PM33820951
143. Tosoian JJ, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder CY, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM: Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. *Urology*: 2021. PM34906585
144. Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, **Palapattu GS**, Vaishampayan UN, Alumkal JJ, Spratt DE, Udager AM, Mehra R: De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. *Med Oncol* 38(3): 26, 2021. PM33586037
145. Zaslavsky A, Adams M, Cao X, Yamaguchi A, Henderson J, Busch-Østergren P, Udager A, Pitchiaya S, Tourdot B, Kasputis T, Church SJ, Lee SK, Ohl S, Patel S, Morgan TM, Alva A, Wakefield TW, Reichert Z, Holinstat M, **Palapattu GS**: Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. *Thromb Res* 200: 64-71, 2021. PM33540294
146. Stangl-Kremser J, Rasul S, Tosoian JJ, Salami SS, Zaslavsky A, Udager A, Mazal P, Kain R, Comperat E, Hacker M, Haug A, Mitterhauser M, Pozo-Salido C, Steinbach C, Hassler MR, Kramer G, Shariat SF, **Palapattu GS**: Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [<sup>177</sup>Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. *Eur Urol Open Sci* 30: 63-66, 2021. PM34337549/PMC8317820
147. Stangl-Kremser J, Mari A, Lai LY, Lee CT, Vince R, Zaslavsky A, Salami SS, Fajkovic H, Shariat SF, **Palapattu GS**: Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review. *J Urol* 208: 854-865, 2021. PM34032495
148. Eyrich NW, Wei JT, Niknafs YS, Siddiqui J, Ellimoottil C, Salami SS, Palapattu GS, Mehra R, Kunju LP, Tomlins SA, Chinnaiyan AM, Morgan TM, Tosoian JJ: Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. *Urol Oncol* 40(1): 4.e1-4.e7, 2022. PM34753659
149. Nallandhighal S, Vince R, Karim R, Groves S, Stangl-Kremser J, Russell C, Hu K, Pham T, Cani AK, Liu CJ, Zaslavsky A, Mehra R, Cieslik M, Morgan TM, Palapattu GS, Udager AM, Salami SS: Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. *Eur Urol Oncol* 5(1): 92-99, 2022. PM34840106
150. Ternov KK, Sønksen J, Fode M, Lindberg H, Kistorp C, Bisbjerg R, Faber J, Klausen TW, Palapattu G, Østergren PB: Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT). *Eur J Cancer* 171: 75-84, 2022. PM35709600

### **Submitted**

1. Polikarpov DM, Campbell DH, Zaslavsky AB, Lund ME, Wu A, Lu Y, **Palapattu GS**, Walsh BJ, Zvyagin AV, Gillatt DA: Glypican-1 as a target for fluorescence molecular imaging of bladder cancer. *Int J Urol*: 2021. (Submitted) PM34498294



2. Stangl-Kremser J, Ahmadi H, Derstine B, Wang SC, Englesbe MJ, Daignault-Newton S, Chernin AS, Montgomery JS, **Palapattu GS**, Lee CT: Psoas muscle mass can predict postsurgical outcomes in patients who undergo radical cystectomy and urinary diversion reconstruction. *Urology*: 2021. (Submitted) PM34437899
3. Cani AK, Hu K, Liu CJ, Siddiqui J, Zheng Y, Han S, Nallandhighal S, Hovelson DH, Xiao L, Pham T, Eyrich NW, Zheng H, Vince R Jr, Tosoian JJ, **Palapattu GS**, Morgan TM, Wei JT, Udager AM, Chinnaiyan AM, Tomlins SA, Salami SS: Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. *Eur Urol Oncol*: 2021. (Submitted) PM33812851

## Book Chapters

1. **Palapattu GS**, Rajfer J: Minimal Evaluation of Erectile Dysfunction. In Sexual Dysfunction, Teloken ed., Teodosio Da Ros, Tannhauser, 2003.
2. **Palapattu GS**: Prostate Cancer: Metastatic. In The Brady Urology Manual, Parsons ed., J.K., 2006. 131-141
3. **Palapattu GS**: Complications of Transurethral Resection of Bladder Tumors. In Complications of Urologic Surgery., Singer ed., Tanega, S.I., 2010. 295-302
4. Morgan T, **Palapattu GS**, Partin A, Wei JT: Prostate Cancer Tumor Markers. In Campbell-Walsh Urology, Wein, Kavoussi, Partin, Peters, eds., Elsevier, 2016. 11th, 108, 2565
5. Morgan TM, **Palapattu GS**, Partin AW, Wei JT: Bio-Markers for Prostate Cancer. In Campbell-Walsh Urology, Partin, Peters, Kavoussi, Dmochowski eds., Elsevier, 2020. 12th, 108

## Abstracts

1. **Palapattu GS**, Stapleton AMF, Kattan MW, Scardino PT: A Change in Technique of Radical Retropubic Prostatectomy Markedly Improves Postoperative Potency, American Urological Association Annual Meeting, Orlando, Florida, 1996.
2. **Palapattu GS**: The Identification of Modifier Loci and Other Genes Involved in the Development of Ovarian Cancer, Howard Hughes Medical Institute Annual Meeting of Medical Student Fellows, Chevy Chase, Maryland, 1996.
3. **Palapattu GS**, Gollapudi GM: The Effects of Testosterone Substitution Therapy on the Prostate of Hypogonadal Men, International Congress of Endocrinology, San Francisco, California, 1996.
4. Shou W, Coerver, KA, Kumar TR, **Palapattu GS**, Matzuk MM: Transgenic Mouse Models for Tumor Suppressor Genes, International Symposium on the Impact of Cancer Biotechnology, Nice, France, 1996.
5. **Palapattu GS**, Kattan M, Scardino PT, Wheeler TM: The Association of Selected Pathological Features with Prostate Cancer (PCa) in a Single Needle Biopsy Accession, American Urological Association Annual Meeting, New Orleans, Louisiana, 1997.
6. Fuchs GJ, **Palapattu GS**, Patel A: Tropical Adjuvant Therapy After Endoscopic Ablation of Upper Urinary Tract Transitional Cell Carcinoma, American Urological Association Annual Meeting, Dallas, Texas, 1999.
7. **Palapattu GS**, Gu Z, Yamashiro J, Kono E, Saffran D, Jakobvits A, Reiter RE: Monoclonal Antibody Against Prostate Stem Cell Antigen (PSCA) Inhibits Prostate Cancer Growth and Metastasis in a Murine Xenograft Model of Prostate Cancer, Society of Basic Urologic Research Annual Meeting, Ft. Myers, Florida, 2000.
8. **Palapattu GS**, Gu Z, Yamashiro J, Kono E, Saffran D, Jakobvits A, Reiter RE: Monoclonal Antibody Against Prostate Stem Cell Antigen (PSCA) Inhibits Prostate Cancer Growth and Metastasis in a Murine Xenograft Model of Prostate Cancer, American Urological Association Annual Meeting, Anaheim, California, 2001.
9. **Palapattu GS**, Amara N, Gu Z, Thomas G, Yamashiro J, Said J, Reiter RM: Prostate Stem Cell Antigen (PSCA) is Overexpressed in Human Transitional Cell Carcinoma, American Urological Association Annual Meeting, Anaheim, California, 2001.
10. **Palapattu GS**, Pantuck A, Dorey F, Belldegrun AB: Collecting System Invasion is a Poor Prognosis Factor in Renal Cell Carcinoma (RCC): Impact on Prognosis and Future Staging Classification, 3rd Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2002.
11. **Palapattu GS**, Rogers CG, Schoenberg MP: Retrospective Analysis of Non-Stented/Running vs. Stented /Interrupted Uretero-Enteric Anastomoses Following Radical Cystectomy: Which is Better?, 4th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2003.

12. **Palapattu GS**, Pantuck A, Dorey F, Belldegrun AB: Collecting system Invasion is a Poor Prognosis Factor in Renal Cell Carcinoma (RCC): Impact on Prognosis and Future Staging Classification, American Urological Association Annual Meeting, Chicago, Illinois, 2003.
13. Rogers C, Bastian P, **Palapattu GS**, Trock B, Schoenberg M, Chan T: Clinical Outcomes of Patients Downstaged at Radical Cystectomy, 5th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2004.
14. **Palapattu GS**, Bastian P, Rogers C, Lin X, Srinivasan Y, Leslie M, Bruce T, Partin A, Nelson W: The Association of Preoperative serum Cell-Free DNA Content and PSA Recurrence Following Radical Prostatectomy, 5th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2004.
15. **Palapattu GS**, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel GE, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Shoenberg MP: Are Patients with pT0 Disease Cured After a Radical Cystectomy?, American Urological Association Annual Meeting, San Antonio, Texas, 2004.
16. **Palapattu GS**, Rogers CG, Hoque M, Schoenberg MP, Sidransky D: Loss of Heterozygosity (LOH) of Single-Nucleotide Polymorphisms (SNPs) Detected in the Urine of Patients with Bladder Cancer: Correlation with Clinical Outcome, American Urological Association Annual Meeting, San Francisco, California, 2004.
17. Gupta A, Lotan Y, Shariat SF, **Palapattu GS** et al: Lymphovascular Invasion Independently Predicts Increased Risk of Distant Recurrence and Decreased Overall Survival in Patients with Transitional Cell Carcinoma, American Urological Association Annual Meeting, San Francisco, California, 2004.
18. Vazina A, Shariat SF, Amiel GE, Lotan Y, Gupta A, Rogers CG, Bastian PJ, **Palapattu GS**, Schoenberg MP, Sagalowsky AI, Lerner SP: Pelvic Lymph Nodes as a Prognosis Factor in Patients Undergoing Radical Cystectomy for Invasive Transitional Cell Carcinoma: A Multi-Center Study, American Urological Association Annual Meeting, San Francisco, California, 2004.
19. Gupta A, Lotan Y, Shariat SF, Karakiewicz PI, Vazina A, **Palapattu GS**, Amiel GE, Evans JL, Dugi D, Rogers CG, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI: Risk Factors for Distant vs. Local Recurrence in Patients Undergoing Radical Cystectomy for Transitional Cell Carcinoma, American Urological Association Annual Meeting, San Francisco, California, 2004.
20. Shen S, Amiel GE, Shariat SF, **Palapattu GS**, Lotan Y, Karakiewicz PI, Vazina A, Rogers CG, Bastian PJ, Gupta A, Schoenberg MP, Arthur AI, Lerner SP: Distant Metastasis of Bladder Cancers: Distribution and Association with Lymph Node Metastasis, Pathologic Stage, and Lymphovascular Invasion, 6th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2005.
21. Gupta A, Shariat S, Nielson M, Bastian P, **Palapattu GS**, Robers CR, Vazina A, Karakiewicz PI, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Outcomes of Patients with Clinical T1 Grade 3 Bladder Urothelial Cell Carcinoma Treated with Radical Cystectomy, 7th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2006.
22. Chun KHF, Briganti A, Shariat SF, **Palapattu GS** et al: Competing Risks Comogram Predicting the Probability of Bladder Cancer Recurrence After Cystectomy Can Reliably Distinguish Between Those Destined to Recur and Those Who May Die of Other Causes Before Recurrence, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.
23. Nielsen ME, Shariat SF, Karakiewicz PI, Amiel GE, Rogers CG, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, **Palapattu GS**: Delay in Radical Cystectomy Over 12 Weeks is Not Associated with Adverse Outcome: Results from the Bladder Research Consortium, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.
24. **Palapattu GS**, Lotan Y, Karakiewicz PI, Vazina A, Rogers CG, Bastian PJ, Nielsen ME, Gupta A, Schoenberg MP, Sagalowsky AI, Lerner SP: Evidence Based Gender Related Outcomes After Radical Cystectomy, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.
25. **Palapattu GS** et al: Internal Validation of a Competing-Risks Survival Nomogram for Patients Treated with Cystectomy for Bladder Cancer, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.
26. Bastian PJ, **Palapattu GS** et al: Preoperative Serum Concentration of Cell-Free Circulating Cancer DNA in Patients with Prostate Cancer and the Risk of Recurrence After Radical Prostatectomy, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.
27. Bastian PJ, Shariat SF, Rogers CG, Amiel GE, Karakiewicz PI, Lotan Y, Gupta A, Vazina A, Sagalowsky AI, Lerner SP, Schoenberg MP, **Palapattu GS**: Prognostic Significance of Deep Muscular Invasion and Extravesical Extension in Pathological Staging of Bladder Cancer After Radical Cystectomy, American Urological Association Annual Meeting, Atlanta, Georgia, 2006.

28. **Palapattu GS** et al: Impact of Concomitant Carcinoma in Situ on Clinical Outcomes After Radical Cystectomy, Impact of concomitant carcinoma in situ on clinical outcomes after radical cystectomy, Atlanta, Georgia, 2006.
29. Golijanin DJ, Singer EA, Chen Y, Manola J, Palapattu GS, Messing EM: Influence of Obesity on Survival in Men Treated with Immediate Versus Deferred Androgen Deprivation Therapy for Node-Positive Prostate Cancer After Radical Prostatectomy and Pelvic Lymphadenectomy, 9th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2008.
30. Singer EA, Golijanin DJ, Chen Y, Manola J, **Palapattu GS**, Messing EM: Influence of Serum Testosterone Level on Survival in Men Treated with Immediate Vs. Deferred Androgen Deprivation for Node-Positive Prostate Cancer After Radical Prostatectomy & Pelvic Lymphadenectomy, 9th Annual Meeting of the Society of Urologic Oncology, Bethesda, Maryland, 2008.
31. Jeldres C, Shariat SF, Suardi N, Lotan Y, Gupta A, Sagalowsky AI, **Palapattu GS**, Bastian PJ, Schoenberg MP, Vazina A, Lerner SP, Karakiewicz PI: A Conditional Nomogram for Prediction of Early Recurrence of Bladder Cancer After Radical Cystectomy, American Urological Association Annual Meeting, Orlando, Florida, 2008.
32. Hutterer GC, Shariat SF, Lotan Y, Bastian PJ, **Palapattu GS** et al: A Systematic Analysis of the Prognostic Ability of Various Nodal Coding Schemes in Bladder Cancer Patients Treated with Radical Cystectomy, American Urological Association Annual Meeting, Atlanta, Georgia, 2008.
33. Suardi N, Shariat SF, Lotan Y, **Palapattu GS** et al: Assessment of the Minimum Number of Lymph Nodes Needed at Radical Cystectomy in Bladder Cancer Patients, American Urological Association Annual Meeting, Orlando, Florida, 2008.
34. Gupta A, Shariat SF, Karakiewicz PI, Bastian PJ, **Palapattu GS**, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Lymphovascular Invasion (LVI) is Independently Associated with Bladder Cancer Recurrence and Survival in Patients with T1 and Negative Lymph Nodes at Radical Cystectomy, American Urological Association Annual Meeting, Orlando, Florida, 2008.
35. Shariat S, Lotan Y, Karakiewicz P, Fradet Y, Ashfaq R, Stein J, Bastian P, Nielsen M, Suardi N, Montorsi F, Groshen S, Muller S, **Palapattu GS**, Rigaud J, Karam J, Heukamp L et al: Multi-Institutional Evaluation of the Value of p53 Immunohistochemical Staining in Patients with pT1-2 N0 Disease at Radical Cystectomy, American Urological Association Annual Meeting, Orlando, Florida, 2008.
36. O'Neil BB, Rothschild JR, Strohsahl CM, Hardy D, **Palapattu GS**, Miller BL: Early Clinical Application of DNA Hairpin Technology to Rapidly Identify Escherichia Coli in Urine, American Urological Association Annual Meeting, Chicago, Illinois, 2009.
37. Golijanin DJ, Singer EA, Chen Y, Manola J, **Palapattu GS**, Messing EM: Influence of Serum Testosterone Level and Body Mass Index on Survival in Men Treated with Immediate Versus Deferred Androgen Deprivation for Node-Positive Prostate Cancer After Prostatectomy and Pelvic Lymphadenectomy, American Urological Association Annual Meeting, Chicago, Illinois, 2009.
38. Golijanin DJ, Singer EA, Marshall J, **Palapattu GS**, Rashid H, Wu G: Robotic-Assisted Laparoscopic Radical Cystectomy with Intracorporeal Ileal Conduit Urinary Diversion: Initial Clinical Experience, American Urological Association Annual Meeting, Chicago, Illinois, 2009.
39. Mener DJ, Cambio AJ, Stoddard DG, **Palapattu GS**: The Impact of HMG-COA Reductase Therapy on Serum PSA Level, American Urological Association Annual Meeting, Chicago, Illinois, 2009.
40. Vareed SK, Panzitt K, Basu S, Putluri V, Dorsey T, Wallace T, Putluri N, Mohammed S, Ittmann M, Kittles R, Michailidis G, Ambs S, **Palapattu GS**, Sreekumar A: Metabolomic Profiling and the Biochemical Basis of Prostate Cancer Racial Disparity, American Association for Cancer Research Distinguished Lecture on The Science of Cancer Health Disparities, San Diego, California, 2012.
41. Li H, Hangwen L, Krou E, Ressler S, Sreekumar A, Gustavo A, Ayala G, Rowley D, **Palapattu GS**: Cancer Testis Antigen SPANXB2 and Prostate Cancer Progression: Human Prostate Stroma Promotes SPANXB2 Expression, American Association for Cancer Research Meeting, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas, 2012.
42. Sonpavde G, Amiel G, Margulis V, Link R, Lerner S, Rag G, Mayer W, **Palapattu GS** et al: Neoadjuvant Therapy Preceding Cytoreductive Nephrectomy to Develop Individualized First-Line Therapy with Everolimus for Advanced Renal Cell Carcinoma (RCC), American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2012.

43. Orr, B, Wei JT, Womble P, Weizer AZ, Mehra R, Montgomery JS, Tomlins SA, Miller, DC, Kunju LP, Hollenbeck BK, Skolarus TA, Lee CT, **Palapattu GS**, Morgan TM: Transperineal Mapping Template Prostate Biopsy Reduces the Likelihood of intervention in Active Surveillance Candidates, 14th Annual Meeting of the Society of Urologic Oncology, Rockville, Maryland, 2013.
44. Panzitt K, Shojaie A, Putluri N, Basu S, Putluri V, Samanta S, Ittmann M, Vergara I, Michailidis G, **Palapattu GS**, Sreekumar A: Integrative Analysis of Transcriptomic and Metabolomic Data Reveals a Critical role for Aminosugar Metabolism in Prostate Cancer, American Association for Cancer Research Annual Meeting, Washington, DC, 2013.
45. Ambani S, Weizer A, Montgomery JS, Miller D, Chang H, Dailey S, Crossley H, Hafez K, Hollenbeck B, Skolarus T, Lee C, Montie J, **Palapattu GS**, Morgan T: Length of Stay Following Radical Cystectomy: How Long is Long Enough?, American Urological Association Annual Meeting, San Diego, California, 2013.
46. Li H, Kou E, Hernandez J, Ressler S, Sreekumar A, Ayala G, Rowley D, Pienta K, **Palapattu GS**: SPANXB2 Expression Increases Prostate Cancer Aggressivity: A New View of Stromal-Epithelial Cell Interaction, American Urological Association Annual Meeting, San Diego, California, 2013.
47. Schade G, Kunju P, Wei JT, Weizer A, Montgomery JS, Miller DC, Hollenbeck B, Hafez K, Wood D, Montie J, **Palapattu GS**, Morgan T: Transperineal Mapping Template Prostate Biopsy After Previous Transrectal Ultrasound Prostate Biopsy Detects Worse Disease Burden, American Urological Association Annual Meeting, San Diego, California, 2013.
48. Kozminski M, **Palapattu GS**, Mehra R, Montgomery JS, Weizer A, Skolarus TA, Hollenbeck B, Miller DC, He C, Tomlins S, Montie J, Feng F, Wood D, Kunju L, Morgan T: Understanding the Impact of the Dominant Nodule and Size of the Prostate on Biochemical Recurrence in Men with Prostate Cancer, American Urological Association Annual Meeting, San Diego, California, 2013.
49. Jackson WC, Johnson SB, Forester C, Li D, Foster B, Song Y, Sandler HM, **Palapattu GS**, Kunju P, Mehra R, Hamstra DA, Yi-Chung F: Gleason Pattern 5 as a Pathologic Predictor of Recurrence, Development of Metastasis, and Prostate Cancer-Specific Death for Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy, Genitourinary Cancers Symposium, Orlando, Florida, 2013.
50. Johnson SB, Jackson WC, Song Y, Foster B, Li D, Foster C, **Palapattu GS**, Mehra R, Kunju P, Feng F, Hamstra DA: Maximum Tumor Diameter as a Predictor for Outcome Following Salvage Radiation for Prostate Cancer, Genitourinary Cancers Symposium, Orlando, Florida, 2013.
51. Jackson WC, Johnson SB, Foster B, Foster C, Song Y, Li D, Sandler HM, **Palapattu GS**, Hamstra D, Feng F: PSA Doubling Time of < 6 Months as the Optimal Cutoff for Predicting Clinically Relevant Outcomes for Men Receiving Salvage Radiation Therapy Post Radical Prostatectomy, Genitourinary Cancers Symposium, Orlando, Florida, 2013.
52. Nicolov E, Ferrati S, Goodall R, Hudson L, Hosali S, Crowley M, **Palapattu GS**, Khera M: Nanotechnology-Based Implant for Long Term Testosterone Replacement, American Urological Association Annual Meeting, Orlando, Florida, 2014.
53. Glazer D, Davenport M, Cohan R, Ellis J, Caoili E, Stein E, Childress J, Masch W, Brown J, Mollard B, Montgomery JS, **Palapattu GS**, Francis I: Focal Nodular Prostatic Peripheral Zone Enhancement on CT to Predict Clinically Significant (Gleason 4+3 and Higher) Prostate Cancer, Genitourinary Cancers Symposium, San Francisco, California, 2014.
54. Koloff Z, Hamstra D, Wei JT, Montgomery JS, Tomlins S, Wu A, Morgan T, Siddiqui J, Paich K, Chinnaiyan A, Feng F, Weizer A, Hollenbeck B, Kunju L, Miller DC, **Palapattu GS**, Mehra R: Impact of Tertiary Gleason Pattern 5 on Prostate Cancer Aggressiveness: Lessons from a Contemporary Single Institution Radical Prostatectomy Series, Genitourinary Cancers Symposium, San Francisco, California, 2014.
55. Saad F, Tomlins S, Sartor A, Nguyen P, **Palapattu G**: Prostate Cancer Tumor Board Audience Challenge, Genitourinary Cancers Symposium, San Francisco, California, <https://meetinglibrary.asco.org/record/87856/video>, 2014.
56. **Palapattu GS**, Cani A, Hovelson D, Mehra R, Montgomery JS, Morgan T, Salami S, Tomlins S, Marks L: Molecular Profiling of Tissue Obtained by Serial MRI Targeted Prostate Biopsy in Men on Active Surveillance for Low Grade Prostate Cancer, 16th Annual Meeting of the Society of Urologic Oncology, Washington, DC, 2015.
57. Miller B, Adams M, Venghatakrishnan H, Giraldez M, Tewari M, **Palapattu GS**, Zaslavsky A: Platelets Possess Prostate Cancer Specific miRNAs: Implications for a Novel Source of Biomarkers, American Association for Cancer Research Annual Meeting, Philadelphia, Pennsylvania, 2015.

58. Magers M, Zahn T, Udager A, Hollenbeck B, Wei JT, Miller DC, Montgomery JS, Siddiqui J, **Palapattu GS**, Jiang H, Mehra R: Anterior Prostate Cancer: Clinicopathologic Characterization with Biopsy Correlation, American Urological Association Annual Meeting, New Orleans, Louisiana, 2015.
59. Kozminski MA, Tomlins S, Singhal U, Lu L, Skolarus TA, **Palapattu GS**, Montgomery JS, Weizer AZ, Mehra R: Defining Adverse Pathology for Lower Risk Men Undergoing Radical Prostatectomy, American Urological Association Annual Meeting, New Orleans, Louisiana, 2015.
60. Singhal U, Lu L, Skolarus TA, **Palapattu GS**, Montgomery JS, Weizer A, Hollenbeck B: Effect of Treatment Delay on Longterm Outcomes in Men Undergoing Radical Prostatectomy for Prostate Cancer, American Urological Association Annual Meeting, New Orleans, Louisiana, 2015.
61. Montgomery JS, Davenport M, Kunju P, Meyer C, **Palapattu GS**, Morgan T, Weizer A, Miller DC: Feasibility and Initial Results of Fluorocholine PET/MRI/TRUS Fusion Prostate Biopsy, American Urological Association Annual Meeting, New Orleans, Louisiana, 2015.
62. Singhal U, Lu L, Skolarus TA, **Palapattu GS**, Montgomery JS, Weizer A, Hollenbeck B: The Role of Perineural Invasion as a Prognostic Tool in Prostate Cancer, American Urological Association Annual Meeting, New Orleans, Louisiana, 2015.
63. Lloyd SM, Gohlke J, Basu S, Bhowmik S, Putluri V, Rajapakshe K, Coarfa C, Ittmann M, **Palapattu GS**, Putluri N, Michailidis G, Sreekumar A: An Integromics Approach Identifies Immune Escape as a Potential Mechanism for Prostate Cancer Disparities, Eighth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Atlanta, Georgia, 2015.
64. Lu L, Singhal U, Skolarus T, **Palapattu GS**, Montgomery JS, Weizer A, Hollenbeck B, Miller DC et al: Prognostic Significance of Perineural Invasion in Localized Prostate Cancer, Genitourinary Cancers Symposium, Orlando, Florida, 2015.
65. **Palapattu GS**, Cani A, Huang J, Hovelson D et al: Progression of Low- to High-Grade Prostate Cancer: Molecular Profiling of Tissue Obtained by Serial Targeted Biopsy, Genitourinary Cancers Symposium, Orlando, Florida, 2015.
66. Salami S, Singhal U, Spratt D, **Palapattu GS**, Hollenbeck B, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Dittamore R, Feng F, Morgan TM: Prevalence and Prognostic Significance of Circulating Tumor Cells (CTC) in Clinically Localized Prostate Cancer, 17th Annual Meeting of the Society of Urologic Oncology, San Antonio, Texas, 2016.
67. Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu V, Zhang Y, Khan A, Lloyd S, Szafran A, Dasgupta S, Bader D, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo D, Chan L, Edwards D, Kaiparettu B, Mitsiades N, Weigel N, Mancini M, Ittmann M, Chinnaiyan A, Putluri N, **Palapattu GS**, Michailidis G, Sreekumar A: Inhibition of Hexose Monophosphate Pathway Promotes Castration Resistant Prostate Cancer, American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, 2016.
68. **Palapattu GS**, Salami SS, Cani AK, Hovelson DH, de la Vega LL, Vandenberg KR, Bratley JV, Liu C, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS: Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer, American Association for Cancer Research Annual Meeting, Clin Cancer Res, 23, 4, 985-991, 2016.
69. **Palapattu GS**, Cani A, Hovelson D, Mehra R, Montgomery J, Morgan T, Salami S, Tomlins S: Molecular Progression of Gleason 6 Prostate Cancer: Tracking of Specific Clones by Image-Guided Biopsy, American Urological Association Annual Meeting, San Diego, California, 2016.
70. **Palapattu GS**, Cani AK, Hovelson D, Mehra R, Montgomery JS, Morgan T, Salami S, Tomlins SA, Marks LS: Molecular Profiling of Prostate Cancer Derived from Serial MRI Targeted Prostate Biopsy in Men on Active Surveillance \*EAU 2016 Best Poster, European Association of Urology Congress, Munich, Germany, 2016.
71. Salami S, Hovelson D, Mathieu R, Susani M, Rioux-Leclercq N, Tracey J, Shariat S, Tomlins SA, **Palapattu GS**: Next Generation Sequencing to Determine the Clonal Origin of Lymph Node Metastasis in Multifocal Prostate Cancer: Defining the Biologically Dominant Nodule \*EAU 2016 3rd Best Poster - Oncology, European Association of Urology Congress, Munich, Germany, 2016.
72. Morgan T, Salami S, Wei JT, **Palapattu GS**, Gursky A, Criekeing W, van Neste L, Mehra R: Ability of an Epigenetic Assay to Identify Anterior Prostate Tumors Based on a Negative 12-core Biopsy, Genitourinary Cancers Symposium, San Francisco, California, 2016.
73. Salami S, Udager A, Miller B, **Palapattu GS**, Tomlins SA, Chinnaiyan A, Spratt D et al: Characterization of Urothelial Carcinoma with Seminal Vesicle Involvement in Locally Advanced Bladder Cancer, Genitourinary Cancers Symposium, San Francisco, California, 2016.

74. Lloyd SM, Gohlke J, Basu S, Bhowmik S, Putluri V, Rajapakshe K, Coarfa C, Ittmann M, **Palapattu GS**, Putluri N, Michailidis G, Sreekumar A: An Integromics Approach Identifies Immune Escape as a Potential Mechanism for Prostate Cancer Disparities, The Ninth American Association for Cancer Research Conference - The Science of Cancer Health Disparities, Ft. Lauderdale, Florida, 2016.
75. Brand L, Zaslavsky A, **Palapattu GS**, Knudsen K: A PSMA-Directed Natural Killer Cell Approach for Prostate Cancer Immunotherapy, American Association for Cancer Research Annual Meeting, Washington, DC, 2017.
76. **Palapattu G**: Tumor Growth and Death, American Society of Clinical Oncologists Annual Meeting, Chicago, Illinois, <https://meetinglibrary.asco.org/record/148673/video>, 2017.
77. Salami S, Hovelson DH, Mathieu R, Kaplan JB, Susani M, Rioux-Leclearcq N, Shariat SF, Tomlins SA, **Palapattu GS**: Comprehensive Molecular Profiling of Multi-Focal Prostate Cancer and Concomitant Lymph Node Metastasis: Implications for Tissue-Based Prognostic Biomarkers, American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2017.
78. Synold TW, Plets M, Tangen CM, Heath EI, **Palapattu GS** et al: Everolimus (EVE) Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III study (NCT01120249)., American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2017.
79. Morgan TM, Chung J, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky A, Hovelson DH, Alva AS, Feng FY, **Palapattu GS**, Taichman RS, Chinnaiyan AM, Tomlins SA: Identification of a CTC-Based Gene Expression Signature Predicting Resistance to Abiraterone and Enzalutamide in mCRPC, American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2017.
80. Alruwaily A, Rohde J, Garneys L, **Palapattu GS**, Ghani K: CO2 Laser Dissection (COLD) Knife Robotic Partial Nephrectomy for Solid Renal Pseudotumors in a Porcine Model: Idea, Development, Exploration, Assessment, Long-Term Monitoring (IDEAL) Stage 0 Study, European Association of Urology Congress, London, England, 2017.
81. Salami S, Hovelson D, Mathieu R, Kaplan J, Susani M, Rioux-Leclercq N, Shariat S, Tomlins S, **Palapattu G**: Comprehensive Molecular Dissection of Multi-Focal Prostate Cancer and Concomitant Lymph Node Metastasis: Implications for Tissue-Based Prognostic Biomarkers, European Association of Urology Congress, London, England, 2017.
82. Morgan T, Singhal U, Wang Y, Henderson J, Niknafs Y, Quao Y, Taichman R, Zaslavsky A, Feng F, **Palapattu GS**, Chinnaiyan A, Tomlins S: Identification of a CTC-Based Prognostic Signature in mCRPC Driven by Aurora Kinase A and Wnt Signaling, European Association of Urology Congress, London, England, 2017.
83. Salami S, Hovelson D, Udager A, Lee M, Curci N, Kaplan J, George A, Davenport M, Tomlins S, **Palapattu G**: Molecular Characterization of Magnetic Resonance Imaging Visible and Invisible Prostate Cancer: Biological Insights and Therapeutic Implications, European Association of Urology Congress, London, England, 2017.
84. Hovelson D, Lazo De La Vega L, McDaniel A, Udager A, Mehra R, **Palapattu GS** et al: Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers to Reveal Discordant Genomic and Transcriptomic Events and Unique Therapeutic Opportunities, Genitourinary Cancers Symposium, Orlando, Florida, 2017.
85. Singhal U, Beesley LJ, **Palapattu GS**, Montgomery JS, Weizer AZ, Hollenbeck BK, Miller DC, Mehra R, Tomlins SA, Spratt DE, Furgal A, Daignault-Newton S, Taylor JMG, Morgan T: Development of a Clinical Tool to Predict Treatment Specific Outcomes of Surgery and Radiation in Clinically Localized Prostate Cancer, 19th Annual Meeting of the Society of Urologic Oncology, Phoenix, Arizona, 2018.
86. Salami S, Kaplan J, Nallandhighal S, Lee M, Yoon J, Hovelson D, Plouffe K, George A, Davenport M, You S, Tomlins S, Curci N, Kim H, Spratt D, Udager A, **Palapattu G**: Molecular Dissection of Magnetic Resonance Imaging Visible and Invisible Prostate Cancer, 19th Annual Meeting of the Society of Urologic Oncology, Phoenix, Arizona, 2018.
87. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung J, Smith DC, Karnes RJ, Chang SL, Feng FY, **Palapattu GS**, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM: Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature, American Association for Cancer Research Annual Meeting, Chicago, Illinois, Mol Cancer Res, 16, 4, 643-654, 2018.
88. Zaslavsky A, Adams M, Wissmueller S, Campbell D, Klingemann H, Walsh B, **Palapattu G**: Glypican-1 as a Novel Immunotherapeutic Target in Prostate Cancer, Genitourinary Cancers Symposium, San Francisco, California, J Clin Oncol, 36, 174, 2018.

89. Hovelson D, Salami S, Kaplan J, Mathieu R, Udager A, Curci N, Lee M, De La Vega L, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport M, Rubin MA, Shariat SF, Tomlins SA, **Palapattu G**: Integrative Molecular Profiling Challenges Robustness of Prognostic Signature Scores in Multifocal Prostate Cancer, Genitourinary Cancers Symposium, San Francisco, California, J Clin Oncol, 36, 96, 2018.
90. Salami SS, Kaplan J, Nallandhighal S, Takhar M, Tosoian JJ, Lee M, Yoon J, Hovelson DH, Plouffe KR, Kaffenberger SD, George AK, Montgomery JS, Davenport M, You S, Tomlins SA, Curci NE, Kim HL, Spratt DE, Udager AM, **Palapattu GS**: Radiogenomic Characterization of Multifocal Prostate Cancer, Genitourinary Cancers Symposium, San Francisco, California, J Clin Oncol, 37, 126, 2019.
91. Tosoian JJ, Salami SS, Nallandhighal S, Jones TA, Plouffe KR, Elkhoury FF, Morgan TM, Liu C, Kunju LP, Montgomery JS, Natarajan S, Sisk A, Tomlins SA, **Palapattu GS**, Marks LS: Molecular Characterization of Longitudinally Tracked Prostate Cancer Foci in Men on Active Surveillance for Low Risk Disease, Genitourinary Cancers Symposium, San Francisco, California, J Clin Oncol, 37, 56, 2019.